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PREAMBLE
It is important that the medical profession play a significant
role in critically evaluating the use of diagnostic procedures
and therapies in the management or prevention of disease
states. Rigorous and expert analysis of the available data
documenting relative benefits and risks of those procedures
and therapies can produce helpful guidelines that improve
the effectiveness of care, optimize patient outcomes, and
affect the overall cost of care favorably by focusing resources
on the most effective strategies.
The American College of Cardiology (ACC) and the
American Heart Association (AHA) have jointly engaged
in the production of such guidelines in the area of cardio-
vascular disease since 1980. This effort is directed by the
ACC/AHA Task Force on Practice Guidelines. Its charge
is to develop and revise practice guidelines for important
cardiovascular diseases and procedures. Experts in the sub-
ject under consideration are selected from both organiza-
tions to examine subject-specific data and write guidelines.
The process includes additional representatives from other
medical practitioner and specialty groups where appropriate.
Writing groups are specifically charged to perform a formal
literature review, weigh the strength of evidence for or
against a particular treatment or procedure, and include
estimates of expected health outcomes where data exist.
Patient-specific modifiers, comorbidities, and issues of pa-
tient preference that might influence the choice of particular
tests or therapies are considered as well as frequency of
follow-up and cost-effectiveness.
These practice guidelines are intended to assist physicians
in clinical decision making by describing a range of generally
acceptable approaches for the diagnosis, management, or
prevention of specific diseases or conditions. These guide-
lines attempt to define practices that meet the needs of most
patients in most circumstances. The ultimate judgment
regarding care of a particular patient must be made by the
physician and patient in light of all of the circumstances
presented by that patient.
The executive summary and recommendations are pub-
lished in the August 24, 1999, issue of Circulation. The full
text is published in the Journal of the American College of
Cardiology. Reprints of both the full text and the executive
summary and recommendations are available from both
organizations.
These guidelines have been officially endorsed by the
North American Society for Pacing and Electrophysiology.
Raymond J. Gibbons, MD, FACC
Chair, ACC/AHA Task Force on Practice Guidelines
I. INTRODUCTION
The ACC/AHA Guidelines for Ambulatory Electrocardi-
ography (AECG) were last published in 1989 (1). Since
then, there have been improvements in solid-state digital
technology that have expanded transtelephonic transmission
of ECG data and enhanced the accuracy of software-based
analysis systems. These advances, in addition to better signal
quality and greater computer arrhythmia interpretation
capabilities, have opened new potential uses for AECG.
Despite these advances, a true automated analysis system
has not been perfected and technician/physician participa-
tion is still essential.
Traditional uses of AECG for arrhythmia detection have
expanded as the result of increased use of multichannel and
telemetered signals. The clinical application of arrhythmia
monitoring to assess drug and device efficacy has been
further defined by new studies. The analysis of transient
ST-segment deviation remains controversial, but consider-
ably more data are now available, especially about the
prognostic value of detecting asymptomatic ischemia. Heart
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rate variability (HRV) analysis has shown promise for
predicting mortality rates in high-risk cardiac patients.
Technological advances with long-term event recorders
have permitted the self-activation of AECG monitors, but
the reliability of fully automatic recording systems has not
been established for routine clinical use. Rapid technological
advances portend further improvements in equipment in the
near future.
These guidelines focus on the use of AECG to aid
clinical decision making. Thus, emphasis will be placed on
the most common clinical uses of the technique. Evaluation
of the clinical utility of a diagnostic test is more difficult than
assessing the efficacy of a therapeutic intervention because
diagnostic tests do not usually have the same direct impact
on patient outcomes (2). In considering the use of AECG in
individual patients, the following factors were important:
1. The technical capacity of the available equipment used
for performing the study and the quality, expertise, and
experience of the professional and technical staff neces-
sary to perform and interpret the study
2. The diagnostic accuracy of the technique
3. The accuracy of the technique as compared with other
diagnostic procedures
4. The effect of positive or negative results on subsequent
clinical decision making
5. The influence of the technique on health-related out-
comes.
The usefulness of AECG techniques in specific clinical
situations is indicated by means of the following classifica-
tion:
Class I: Conditions for which there is evidence and/or
general agreement that a given procedure or
treatment is useful and effective
Class II: Conditions for which there is conflicting ev-
idence and/or a divergence of opinion about
the usefulness/efficacy of a procedure or treat-
ment
Class IIa: Weight of evidence/opinion is in
favor of usefulness/efficacy
Class IIb: Usefulness/efficacy is less well es-
tablished by evidence/opinion
Class III: Conditions for which there is evidence and/or
general agreement that the procedure/
treatment is not useful/effective, and in some
cases may be harmful
This report includes brief descriptions of instrumentation
and systems and reviews the use of AECG for 1) arrhythmia
detection; 2) prognosis; 3) efficacy of antiarrhythmic ther-
apy; 4) assessing pacemaker function and implantable
cardioverter-defibrillator (ICD) function; 5) detecting myo-
cardial ischemia; and 6) use in children. Tables appear in
each section that summarize the recommendations for that
particular application.
The Committee reviewed and compiled pertinent pub-
lished reports by computerized and hand searches, excluding
abstracts, and the recommendations made are based on
these reports. Data tables are presented where multiple
reports are available, but formal meta-analyses were not
performed because of the nature of the available data and
cost constraints. When few or no data existed, this is
identified in the text, and recommendations are based on
committee consensus. A complete list of the multiple
publications on AECG is beyond the scope of this commu-
nication, and only selected references are included, empha-
sizing new data since 1989. Finally, although cost consid-
erations are important, there were insufficient data to
present formal cost-effectiveness analyses. However, cost
was considered in general terms for the recommendations.
The Committee membership consisted of acknowledged
experts in AECG, general cardiologists, cardiologists with
expertise in arrhythmias and pacing, 1 family practitioner,
and 1 general internist. Both the academic and private
practice sectors are represented. No member reported a
conflict of interest bearing on committee participation. The
guidelines will be considered current unless the Task Force
publishes revisions or a withdrawal.
II. AECG EQUIPMENT
Since the introduction of portable devices to record the
ECG in 1957 by Dr Norman Holter, there have been major
advances in recording and playback methodologies. The
widespread and inexpensive availability of personal comput-
ers and workstations has allowed for the development of
extremely sophisticated and automated signal processing
algorithms. Current AECG equipment provides for the
detection and analysis of arrhythmias and ST-segment
deviation as well as more sophisticated analyses of R-R
intervals, QRS-T morphology including late potentials,
Q-T dispersion, and T-wave alternans.
There are 2 categories of AECG recorders. Continuous
recorders, typically used for 24 to 48 hours, investigate
symptoms or ECG events that are likely to occur within
that time frame. Intermittent recorders may be used for long
periods of time (weeks to months) to provide briefer,
intermittent recordings to investigate events that occur
infrequently. Two basic types of intermittent recorders have
slightly different utility. A loop recorder, which is worn
continuously, may be particularly useful if symptoms are
quite brief or if symptoms include only very brief incapac-
itation such that the patient can still activate the recorder
immediately afterward and record the stored ECG. It is
sometimes possible for a family member to activate the
recorder if the patient actually loses consciousness. How-
ever, even a loop recorder with a long memory may not be
useful if loss of consciousness includes prolonged disorien-
tation on awakening that would prohibit the patient from
activating the device. Newer loop recorders can be im-
planted under the skin for long-term recordings, which may
914 Crawford et al. JACC Vol. 34, No. 3, 1999
ACC/AHA Guidelines for Ambulatory Electrocardiography September 1999:912–48
be particularly useful for patients with infrequent symptoms.
Another type of intermittent recorder is the event recorder,
which is attached by the patient and activated after the onset
of symptoms. It is not useful for arrhythmias that cause
serious symptoms such as loss of consciousness or near loss
of consciousness because these devices take time to find,
apply, and activate. They are more useful for infrequent, less
serious but sustained symptoms that are not incapacitating.
For this review, equipment will be described for the record-
ers first and then for the playback systems. Only selected
technical details are presented in this review. A more
complete description of the technical requirements for
AECG equipment can be found in the 1994 American
National Standard developed by the Association for the
Advancement of Medical Instrumentation (3).
A. Continuous Recorders
Conventional AECG recorders typically are small, light-
weight devices (8 to 16 oz) that record 2 or 3 bipolar leads.
They contain a quartz digital clock and a separate recording
track to keep time. They are generally powered by a 9-V
disposable alkaline battery and a calibration signal automat-
ically inserted when the device is energized. A patient-
activated event marker is conveniently placed on the device
for the patient to indicate the presence of symptoms or to
note an event. The frequency response of the recording and
playback system should be reasonably flat, from 0.67 to
40 Hz.
The conventional format for recording has been magnetic
cassette-type tape. Tape speed typically is 1 mm/s, and
speed is kept constant by an optical speed sensor on the
flywheel and a crystal controlled phase locked loop. This
technology has been the standard for many years and has the
advantage of being inexpensive and providing a permanent
record of all electrical activity throughout the recording
period. This format allows for playback and interrogation of
the entire recording period (so-called “full disclosure”). It is
adequate to detect abnormalities of rhythm or conduction,
but it may be limited for recording low-frequency signals
such as the ST segment. An inadequate low-frequency
response or marked phase shift from the higher-frequency
QRS signal can lead to artifactual distortion of the ST
segment that may be incorrectly interpreted as ischemic,
particularly using some amplitude-modulated (AM) systems
(4). More recent AM systems have been designed with
improved low-frequency recording and playback character-
istics and have been documented to record accurately
ST-segment deviation (5) and even T-wave alternans (6).
The frequency-modulated (FM) systems avoid this bias
because they can be designed with an ideal low-frequency
response without a low-frequency “boost” and are less prone
to phase shift (4). However, FM systems are not as widely
available, are more costly, and are subject to more baseline
“noise” than AM systems (4). Regardless of whether AM or
FM recording techniques are used, the tape itself may
stretch and consequently distort the electrical signal.
Rapidly evolving technologies now allow for direct re-
cording of the ECG signal in a digital format by use of
solid-state recording devices. The direct digital recording
avoids all of the biases introduced by the mechanical
features of tape recording devices and the problems associ-
ated with recording data in an analog format, which requires
analog-to-digital conversion before analysis. ECG signals
can be recorded at up to 1000 samples per second, which
allows for the extremely accurate reproduction of the ECG
signal necessary to perform signal averaging and other
sophisticated ECG analyses. These solid-state recordings
can be analyzed immediately and rapidly, and some record-
ers are now equipped with microprocessors that can provide
“on-line analysis” of the QRS-T complex as it is acquired. If
specific abnormalities are detected, such as ST-segment
deviation, immediate feedback can be provided to the
patient. The solid-state format also provides for ready
electronic data transfer to a central analysis facility. Limi-
tations of this technology include its expense, the limited
storage capacity of digital data, and, in the case of on-line
analysis, reliance on a computer algorithm to identify
abnormalities accurately. A 24-hour recording includes
approximately 100,000 QRS-T complexes and requires
almost 20 megabytes of storage per channel. Problems of
storage capacity have been approached with 2 techniques of
“compressing” the recorded data: 1) “lossy” compression of
QRS-T complexes with very high compression ratios and 2)
“loss-less” compression combined with enhanced storage
capacity. Much of the reluctance of physicians to use
solid-state methodologies in the past has been due to lack of
faith in the “lossy” compression methods because their
accuracy is dependent on the ability of the microprocessor to
distinguish important physiological abnormalities from ar-
tifact or a wandering baseline. Confirmation of the “deci-
sions” by the microprocessor cannot be made because the
primary data are not recorded in their entirety and cannot be
retrieved nor reproduced without error (ie, non-full disclo-
sure). Because it is essential that representative ECG
complexes from all ischemic episodes or arrhythmias be
confirmed by an experienced technician or physician, the
lack of full disclosure may limit the reliability of the
compressed storage method (7,8). Accuracy of the on-line
interpretations also may be different for ischemia versus
arrhythmia analyses (9). The clinical usage of “lossy” com-
pressed recordings and on-line interpretations is limited.
There are insufficient data comparing analyses based on
full-disclosure recordings versus “lossy” compressed record-
ings that are interpreted on-line to determine the suitability
of the high-ratio compression methodologies for wide-
spread use.
The newer technologies of enhanced storage capacity
allow for all of the technical advantages of solid-state
recording and now allow “full disclosure” by using loss-less
compression methods, which reduce the amount of storage
required by a factor of 3 to 5 but still permit reconstruction
of the waveform with no loss of information. The storage
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methodologies available include a flash memory card or a
portable hard drive. Flash cards are very small, compact
storage devices, which are about the size of a credit card and
have the capacity to store 20 to 40 megabytes of data. The
flash cards are removed from the recording device once the
recording is completed and are inserted into a separate
device where the data can be played back and analyzed or
the data can be transmitted electronically to another loca-
tion for analysis. Miniature hard drives utilize the same
technology used in laptop computers and can store more
than 100 megabytes of data. Unlike flash cards, the hard
drives are not removed from the recorder but the data are
downloaded to another storage device or electronically
transferred.
B. Methods of Electrode Preparation and Lead Systems
Used
The skin over the electrode area should be shaved, if
necessary, gently abraded with emery tape, and thoroughly
cleansed with an alcohol swab. To optimize recordings of
the low-frequency ST segment, skin resistance may be
measured with an impedance meter once the electrodes are
applied. The measured resistance between electrodes should
be #5 kV and preferably #2 kV.
Most recorders utilize 5 or 7 electrodes attached to the
chest, which record the signal from 2 or 3 bipolar leads onto
2 or 3 channels. The third channel may be dedicated to
recording pacemaker activity. A variety of bipolar lead
configurations are used, the most common being a chest
modified V5 (CM5), a chest modified V3 (CM3), and a
modified inferior lead. If a patient undergoing AECG
monitoring for ischemia has had an exercise test with
ischemic changes, the AECG lead configuration should
mimic those leads with the greatest ST-segment change
during exercise. A test cable can be connected from the
recorder to a standard ECG machine when the device is
attached to the patient to verify amplitude, rate, and
morphology of waveforms that will be recorded. Once the
leads have been applied, before the patient leaves the
laboratory, supervised recordings should be made with the
patient in the standing, sitting, right and left lateral decu-
bitus, and supine positions to ensure that artifactual ST-
segment deviation does not occur.
In a recent study of simultaneous recordings of a 3-lead
AECG and a conventional 12-lead ECG recording during
an exercise treadmill test (10), CM5 was the single lead with
the highest sensitivity (89%) in detecting myocardial isch-
emia. The addition of CM3 to CM5 increased sensitivity to
91%, and the addition of an inferior lead to CM5 increased
the sensitivity to 94%, particularly improving detection of
isolated inferior ischemia. The combination of all 3 AECG
leads had a sensitivity of 96%, only 2% more than the best
combination of 2 leads (CM5 plus an inferior lead). Thus,
routine identification of ischemic ST-segment deviation
may only require 2 leads. Use of an inverse Nehb J lead, in
which the positive electrode is placed on the left posterior
axillary line, may enhance sensitivity to detect ischemia (11).
Some new AECG monitor systems can record a true
12-lead ECG, whereas others derive a 12-lead ECG from
3-lead data through the use of a mathematical transform.
C. Variability of Arrhythmias and Ischemia and Optimal
Duration of Recording
The day-to-day variability of the frequency of arrhyth-
mias or ST-segment deviation is substantial (12–22). Most
arrhythmia studies use a 24-hour recording period, although
yield may be increased slightly with longer recordings or
repeated recordings (23). Major reductions in arrhythmia
frequency are necessary to prove a treatment effect. To
ensure that a change is due to the treatment effect and not
to spontaneous variability, a 65% to 95% reduction in
arrhythmia frequency after an intervention is necessary (12).
The variability of the frequency, duration, and depth of
ischemic ST-segment depression is also marked (24–28).
Because most ischemic episodes during routine daily activ-
ities are related to increases in heart rate (29), the variability
of ischemia between recording sessions may be due to
day-to-day variability of physical or emotional activities
(30). It is therefore essential to encourage similar daily
activities at the time of AECG recording. The optimal and
most feasible duration of recording to detect and quantify
ischemia episodes is probably 48 hours (25). Most patients
are quite comfortable wearing the recorder for 48 hours.
The variability of AECG ischemia strongly influences
clinical trial design to identify the efficacy of a therapeutic
intervention (26,28). For example, a 75% reduction in the
number of ischemic episodes would be necessary to achieve
statistical significance within an individual patient moni-
tored for 48 hours before and after an intervention (28).
Families of relations have been calculated for sample size
estimates and statistical power for intervention trials
(26,28).
D. Intermittent Recorders
These devices, which are also termed “event recorders,”
include those that record and store only a brief period of
ECG activity when activated by the patient in response to
symptoms and those that record the ECG in a continuous
manner but store only a brief period of ECG recording (eg,
5 to 300 seconds) in memory when the event marker is
activated by the patient at the time of a symptom (loop
recorder). These devices often use solid-state memory and
can transfer data readily over conventional telephone lines.
These recorders can be used for prolonged periods of time
(many weeks) to identify infrequently occurring arrhythmias
or symptoms that would not be detected with a conventional
24-hour AECG recording. Newer loop recorders can be
implanted for longer-term monitoring. An event recorder
relies on rapid placement of electrodes, such as paddles
connected to the recorder or a wrist bracelet, to record the
ECG at the time of the symptom. Loop recorders use
continuously worn electrodes. The recorded signal can be
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transmitted to a receiving station or may be saved in
memory and transferred at a later time to a central analysis
facility.
Intermittent recorders have the advantage of being small
and light, easy to use, and can be programmed to record
many short episodes during an extended period of time (in
most cases up to 30 days). Single-, 2-, 3-, and reconstructed
12-lead formats are available.
E. AECG Recording Capabilities Associated With
Pacemakers and ICDs
Most current ICDs continually monitor the intracardiac
electrogram and store in memory a summary of tachycardia
and bradycardia episodes as well as a brief electrogram
meeting prespecified criteria preceding and following each
therapeutic discharge.
Intracardiac electrograms may be recorded from a variety
of leads and electrode pairs, depending on the equipment
used (31). These devices can store only a limited number or
duration of recordings (32). Many pacemakers have the
capability to calculate heart rate for a selected period of
time. See Section VII for further description of recording
capabilities of current pacemakers and ICD devices.
F. Playback Systems and Methods of Analysis
Most current playback systems use generic computer
hardware platforms running proprietary software protocols
for data analysis and report generation. Facsimile, modem,
network, and Internet integration allow for rapid distribu-
tion of AECG data and analyses throughout a healthcare
system. Signals recorded in analog format (ie, magnetic
tape) are digitized at either a rate of 128 or 256 samples per
second for subsequent analysis. The clock track on the tape
can compensate for variations in tape speed by a phase lock
loop circuit. The resolution is usually at least 8 bits and the
sampling rate is nominally 128 samples per second. The
signal amplitude can be adjusted by the technician on the
basis of the calibration signal recorded automatically at the
initiation of each recording. Tape playback and scanning
options include rapid playback with either superimposition
(up to 1000 times real time) or page-type displays.
It is critical that each classification of arrhythmia mor-
phology and each ischemic episode be reviewed by an
experienced technician or physician to ensure accurate
diagnosis because AECG recordings during routine daily
activities frequently have periods of motion artifact or
baseline wander that may distort the ST-segment or QRS
morphology. The presence of artifacts can be minimized by
good skin preparation, use of high-quality ECG electrodes
and monitoring leads, lead placement secured by loops of
the electrode cable, and awareness of ST-segment deviation
caused by changes in body position. Although the identifi-
cation of ischemia made by the computer algorithm alone
may be helpful, the interpretations are frequently found to
be incorrect when assessed by an experienced observer.
Overreading is essential. In an experienced laboratory, the
interobserver and intraobserver agreement for the presence
and characterizations of ischemic episodes should be high.
Preliminary studies suggest that there may be differences in
interpretation of ST-segment activity among different lab-
oratories. Much more investigation concerning the unifor-
mity of interpretations of ischemic ST-segment deviation is
necessary before widespread application of ischemia moni-
toring is feasible and reliable. Interobserver and intraob-
server agreement is excellent for categorization of arrhyth-
mias, but discrepancies of 10% to 25% in total ventricular
arrhythmia counts for the same recording may occur if
frequent or complex arrhythmias are present (33).
1. Arrhythmia Analysis. Each beat is classified as normal,
ventricular ectopic, supraventricular ectopic, paced, other, or
unknown, and a template for each type of abnormality is
created. The computer tabulates the number of ectopic beats
in each template. Summary data describing the frequency of
atrial and ventricular arrhythmias are displayed typically in
both tabular and graphical formats. The system automati-
cally stores strips of significant arrhythmia events detected
as well as patient events and entered diary notation times.
2. Ischemia Analysis. The QRS-T morphology must be
carefully scrutinized to ensure that it is suitable for inter-
pretation to identify ischemic changes (34). The rhythm
should be normal sinus rhythm. The baseline ST segment
should have #0.1 mV deviation, and the morphology
ideally should be gently upsloping with an upright T wave.
Although an ST segment that is flat or associated with an
inverted T wave may still be interpretable, downsloping or
scooped ST-segment morphology should be avoided. The
R-wave height of the monitored lead should be $10 mm.
Patients whose 12-lead ECG demonstrates left ventricular
(LV) hypertrophy, preexcitation, left bundle-branch block,
or nonspecific intraventricular conduction delay $0.10 sec-
ond are not suitable for detecting ischemia by AECG. The
lead selected for AECG ischemia monitoring should not
have a Q wave $0.04 second or marked baseline ST-
segment distortion. ST-segment deviation in the presence
of right bundle-branch block may be interpretable, espe-
cially in the left precordial leads. Medications such as
digoxin and some antidepressants distort the ST segment
and preclude accurate interpretation of ST-segment devia-
tion. ST-segment deviation is usually tracked by the use of
cursors at the P-R segment to define the isoelectric refer-
ence point and at the J-point and/or 60 to 80 ms beyond the
J-point to identify the presence of ST-segment deviation.
Ischemia is diagnosed by a sequence of ECG changes that
include flat or downsloping ST-segment depression $0.1
mV, with a gradual onset and offset that lasts for a
minimum period of 1 minute. Each episode of transient
ischemia must be separated by a minimum duration of at
least 1 minute, during which the ST segment returns back
to baseline (1 3 1 3 1 rule) (35), although many investi-
gators prefer a duration of at least 5 minutes between
episodes. We recommend a 5-minute interval between
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episodes because the end of one episode and the onset of
another episode will take longer than 1 minute to be
physiologically distinct.
During superimposition scanning, the system displays the
normal complexes used for ST-segment measurement. The
magnitude of ST-segment deviation and the slope of the ST
segment typically is identified and presented as part of a
24-hour trend. Episodes of ST-segment deviation are char-
acterized by identification of an onset and offset time,
magnitude of deviation, and heart rate before and during the
episode. Representative ECG strips at the time of ST-
segment deviation in real time may be provided in the report
format. Ischemic episodes are displayed in a summary table.
Miniaturized full-disclosure display can be printed for all or
part of the 24-hour recording.
G. Emerging Technologies
There are a number of important new technologies that
hold promise for the future. During the playback of the
recorded ECG signal and the analysis process, there are
electrophysiological variables that can be measured other
than arrhythmias and ST-segment deviation. These include
T-wave alternans (6), Q-T interval dispersion (36), and
signal-averaged analysis (37). For these analyses, high-
resolution data are necessary, which may require data
acquisition at rates up to 1000 samples per second (38).
III. HEART RATE VARIABILITY
A. General Considerations
Analysis of R-R variability has been available for several
years and is generally referred to as HRV. The balance
between the cardiac sympathetic and vagal efferent activity is
evidenced in the beat-to-beat changes of the cardiac cycle.
Determination of this HRV is often performed to assess
patients with cardiovascular disease. Several systems are
commercially available to analyze spectral and temporal
parameters of HRV.
Analysis of the beat-to-beat oscillation in the R-R
interval is generally performed by 2 methods. Spectral
analysis provides an assessment of the vagal modulation of
the R-R interval. Spectral analysis is most commonly
accomplished by fast Fourier transformation to separate
R-R intervals into characteristic high (0.15 to 0.40 Hz), low
(0.04 to 0.15 Hz), very low (0.0033 to 0.04 Hz), and ultra
low (up to 0.0033 Hz) frequency bands. Spectral measures
are collected over different time intervals (approximately 2.5
to 15 minutes), depending on the frequency being analyzed
(39). Parasympathetic tone is primarily reflected in the
high-frequency (HF) component of spectral analysis (40–
42). The low-frequency (LF) component is influenced by
both the sympathetic and parasympathetic nervous systems
(43,44). The LF/HF ratio is considered a measure of
sympathovagal balance and reflects sympathetic modula-
tions (45).
Nonspectral or time domain parameters involve comput-
ing indexes that are not directly related to specific cycle
lengths. This method offers a simple means of defining
patients with decreased variability in the mean and standard
deviations of R-R intervals. Time domain parameters ana-
lyzed include mean R-R, the mean coupling interval be-
tween all normal beats; SDANN, standard deviation of the
averaged normal sinus R-R intervals for all 5-minute seg-
ments of the entire recording; SDNN, standard deviation of
all normal sinus R-R intervals; SDNN index, mean of the
standard deviations of all normal R-R intervals for all
5-minute segments of the entire recording; pNN50, the
percentage of adjacent R-R intervals that varied by more
than 50 ms; and rMSSD, the root mean square of the
difference between the coupling intervals of adjacent R-R
intervals. Another time domain measure of HRV is the
triangular index, a geometric measure obtained by dividing
the total number of all R-R intervals by the height of the
histogram of all R-R intervals measured on a discrete scale
with bins of 7.8 ms. The height of the histogram equals the
total number of intervals found in the modal bin. These 2
analytical techniques are complementary in that they are
different mathematical analyses of the same phenomenon.
Therefore certain time and frequency domain variables
correlate strongly with each other (Table 1).
B. Technical Requirements for Recording and Analysis
1. Duration of Recording. Depending on the specific
indication for analysis of HRV, either long-term (24-hour)
or short-term (5-minute) recordings are made. HRV in-
creases with increased periods of observation, and it is
important to distinguish ranges on the basis of duration
of recording. The Task Force of the European Society of
Cardiology (ESC) and the North American Society of
Pacing and Electrophysiology (NASPE) (45) provided fre-
quency ranges for each parameter of HRV obtained during
short- and long-term recordings (Table 2).
Frequency domain methods are preferable for short-term
Table 1. Components of HRV
Spectral
Component
Time-Domain
Correlates
Normal Measures
for 24 Hours
HF rMSSD ,15 h
pNN50 ,0.75%
LF SDNN index ,30 ms
VLF SDNN index ,30 ms
ULF SDNN ,50 ms
SDANN ,40 ms
HRV index . . .
TP SDNN ,50 ms
HRV index . . .
VLF indicates very-low frequency; ULF, ultra-low frequency; TP, total power;
SDNN index, mean of standard deviation of R-Rs; HRV index, integral of the total
number of normal R-Rs divided by the maximum of the density distribution (an
expression of overall 24-hour HRV).
From References 54, 56, and 57.
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recordings. Recording should last at least 10 times the
duration of the wavelength of the lowest frequency under
investigation. For example, recordings should be approxi-
mately 1 minute for short-term evaluation of the HF and 2
minutes for evaluation of LF. The authors of the ESC/
NASPE Task Force recommend standardization at
5-minute recordings for short-term analysis of HRV (45),
which is endorsed by this Task Force.
2. Artifact and Arrhythmias. No matter whether short- or
long-term data are analyzed, the analysis of HRV depends
on the integrity of the input data. Most systems obtain
computer-digitized ECG signals. The R-R intervals are
derived either on-line or off-line. The rate of digitization
varies from system to system. Many commercial AECG
systems have a digitization rate of 128 Hz, which is not
optimal for some experimental short-term recordings but is
useful for long-term recordings in adults (46).
To optimize the temporal accuracy of R-wave peak
identification, especially when the digitization rate is below
250 Hz, a template matching or interpolation algorithm
should be used (45,47,48). Similarly, artifact or noise in the
ECG signal can create errors in R-wave timing. Several
approaches to this problem have been taken and include
smoothing or filtering the digitized data (47–49). Although
these methods help to reduce inaccuracies created by re-
corded noise, careful patient preparation and maintenance
of recording equipment is very important to eliminate noise
before it occurs.
If analog recording devices are used, rates of digitization
are not a factor, but noise and other errors in R-wave timing
remain important. AECG systems that record on magnetic
tape for off-line processing can introduce errors related to
tape stretch. The ESC/NASPE Task Force (45) provided
guidelines for the routine evaluation of recording systems
through simulated calibration signals with known charac-
teristics.
A problem with ambulatory recordings for the determi-
nation of HRV is motion-related artifact. Missing R waves
or spuriously detected beats can lead to large deviations in
the R-R interval. Manual overview can usually detect these
errors but can be tedious. Distribution-based artifact detec-
tion algorithms are best used to assist the visual approach
(50–52).
An additional factor that introduces difficulties in the
analysis of HRV is the presence of cardiac arrhythmias.
HRV analysis is not possible with persistent atrial fibrilla-
tion. Intermittent abnormal heartbeats can distort the nor-
mal R-R intervals. Although HRV may be useful in
predicting or characterizing abnormal rhythms, the presence
of abnormal heartbeats must be processed in some way to
avoid errors in the assessment of HRV. Two methods for
handling abnormal heartbeats include interpolation of oc-
casional abnormal beats (53) and limiting analysis to seg-
ments that are free of abnormal beats. Both methods have
limitations, and application of both may be appropriate.
However, in publications in which assumptions have been
made, they must be stated clearly.
C. Day-to-Day Variability
In normal subjects, Kleiger et al (54) found 24-hour
ambulatory recordings to reveal large circadian differences in
the R-R interval, LF power, HF power, and LF/HF ratio.
Table 2. Selected Frequency Domain Measures of HRV
Variable Units Description Frequency Range
Analysis of Short-Term Recordings (5 min)
5-min total power ms2 The variance of NN intervals over the
temporal segment
’#0.4 Hz
VLF ms2 Power in the VLF range #0.04 Hz
LF ms2 Power in the LF range 0.04–0.15 Hz
LF norm nu LF power in normalized units
LF/(total power2VLF)3100
HF ms2 Power in the HF range 0.15–0.4 Hz
HF norm nu HF power in normalized units
HF/(total power2VLF)3100
LF/HF Ratio LF [ms2]/HF [ms2]
Analysis of Entire 24 Hours
Total power ms2 Variance of all NN intervals ’#0.4 Hz
ULF ms2 Power in the ULF range #0.003 Hz
VLF ms2 Power in the VLF range 0.003–0.04 Hz
LF ms2 Power in the LF range 0.04–0.15 Hz
HF ms2 Power in the HF range 0.15–0.4 Hz
a Slope of the linear interpolation of
the spectrum in a log-log scale
’#0.04 Hz
VLF indicates very-low frequency; ULF, ultra-low frequency.
Reprinted with permission from Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability:
standards of measurement, physiological interpretation, and clinical use. Circulation 1996;93:1043–65.
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Kleiger et al also described 3- to 4-fold changes in R-R
variability between 5-minute segments of the same hour.
However, the mean values for the LF and HF power were
almost identical from day to day. Power spectral measures of
R-R variability averaged across a 24-hour period were also
essentially constant. Large differences were seen among the
5-minute intervals during the day (55). HRV in the normal
population is affected by age and sex. Recent data have
shown that SDNN index, rMSSD, and pNN50 in healthy
people over the age of 60 years may actually fall below levels
that have been associated with increased mortality rates.
Younger women have less HRV than their age-matched
counterparts, but these differences disappear by age 50 years.
In subjects with coronary artery disease (CAD), Bigger et al
(56) found no significant differences between 2 consecutive
24-hour recordings. Recommendations for the use of HRV
analysis follow in Section V. K.
IV. ASSESSMENT OF SYMPTOMS THAT MAY BE
RELATED TO DISTURBANCES OF HEART RHYTHM
A. Symptomatic Arrhythmias
One of the primary and most widely accepted uses of
AECG is the determination of the relation of a patient’s
transient symptoms to cardiac arrhythmias (12,58,59).
Some symptoms are commonly caused by transient arrhyth-
mias: syncope, near syncope, dizziness, and palpitation.
However, other transient symptoms are less commonly
related to rhythm abnormalities: shortness of breath, chest
discomfort, weakness, diaphoresis, or neurological symp-
toms such as a transient ischemic attack. Vertigo, which is
usually not caused by an arrhythmia, must be distinguished
from dizziness. More permanent symptoms such as those
seen with a cerebrovascular accident can be associated less
commonly with an arrhythmia, such as embolic events that
occur with atrial fibrillation. A careful history is essential to
determine if AECG is indicated.
If arrhythmias are thought to be causative in patients with
transient symptoms, the crucial information needed is the
recording of an ECG during the precise time that the
symptom is occurring. With such a recording, one can
determine if the symptom is related to an arrhythmia. Four
outcomes are possible with AECG recordings. First, typical
symptoms may occur with the simultaneous documentation
of a cardiac arrhythmia capable of producing such symp-
toms. Such a finding is most useful and may help to direct
therapy. Second, symptoms may occur while an AECG
recording shows no arrhythmias. This finding is also useful
because it demonstrates that the symptoms are not related to
rhythm disturbances. Third, a patient may remain asymp-
tomatic during cardiac arrhythmias documented on the
recording. This finding has equivocal value. The arrhythmia
may be useful as a clue to a more severe arrhythmia that
actually causes symptoms. For example, nonsustained ven-
tricular tachycardia recorded while the patient is asymptom-
atic may be a clue that the patient has a more serious
ventricular tachycardia at other times, causing near syncope
or syncope. Likewise, asymptomatic bradycardia may be a
clue that symptoms may occur when the heart rate is even
slower. However, asymptomatic arrhythmias are common,
even in the general population without heart disease (60–
63). Therefore the recorded arrhythmia may or may not be
relevant to the symptoms. Fourth, the patient may remain
asymptomatic during the AECG recording, and no arrhyth-
mias are documented. This finding is not useful.
It is imperative that the physician and patient be persis-
tent in attempting to record the cardiac rhythm simulta-
neous with transient symptoms. This may require multiple
24- or 48-hour AECG recordings or event recorders
(23,64 – 69), especially for infrequent symptoms. The
rhythm must be recorded during and not after the symp-
toms have occurred. The utility of AECG will be deter-
mined by the frequency, severity, duration, and conditions
under which the symptoms occur. Less frequent arrhyth-
mias will require more attempts to record. Significant
cardiac arrhythmias are more likely to occur in patients with
serious heart disease, so it is more likely that transient
symptoms can be correlated to arrhythmias in the severely ill
cardiac patient. It is essential that a complete and detailed
history and physical examination be taken, and it is often
necessary to perform blood work, a chest radiograph, a
12-lead ECG, and/or an echocardiogram as a part of the
initial evaluation. Careful clinical judgment must be exer-
cised. Causes of symptoms other than arrhythmias must be
considered and appropriate additional studies obtained.
Under some circumstances, particularly in patients with
exertional symptoms, an exercise test might give a higher
yield for correlation between symptoms and cardiac rhythm.
Electrophysiological studies and tilt-table testing also may
be considered in certain circumstances. If symptoms are
severe, monitoring may need to be performed in-hospital
continuously on telemetry. However, the sensitivity and
specificity of automatic rhythm monitoring alarms may be
inferior to analysis of AECGs.
B. Selection of Recording Technique
The characteristics of the patient’s symptoms will often
determine the choice of recording techniques. Selection of
technique must be individualized. Specific indications for
the different types of recorders should not be defined here
because such detail would place undue limits on clinical
judgment. Continuous AECG recording may be particu-
larly useful in patients who have complete loss of conscious-
ness and would not be able to attach or activate an event
recorder. Continuous AECG recording is particularly useful
if symptoms occur daily or almost daily, although most
patients do not have episodic symptoms this frequently.
Such a recording should include a patient diary of symptoms
and activities and the use of an event marker. The event
marker is activated whenever the patient has typical symp-
toms, simplifying the identification of the point in time
during the recording when symptoms occurred. Usually
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24-hour recordings are performed, although yield may be
increased slightly with longer recordings or repeated record-
ings (23).
Many patients have symptoms occurring weekly or
monthly, in which case a single continuous AECG record-
ing probably will not be useful. An intermittent or event
recorder (which is often capable of transtelephonic down-
loading) is more useful for infrequent symptoms (70–75).
Some rhythm recording devices are implanted surgically
and include pacemakers, cardioverter-defibrillators, and
newly developed ECG recorders (76,77). Their utility is
limited by the need for an invasive procedure.
C. Specific Symptoms
Few studies have evaluated the sensitivity, specificity,
positive and negative predictive values, and cost-
effectiveness of the various recording techniques in patients
with symptoms potentially related to cardiac arrhythmias.
Only in the subset of patients with syncope are detailed data
available.
1. Syncope. The diagnostic evaluation of syncope is deter-
mined by many clinical factors (59,64–67,69,76,78,79).
Many studies combine evaluation of syncope with near
syncope and/or dizziness (Table 3) and use different ar-
rhythmia end points to define a “positive” study (66–
69,78,79). Unfortunately, the yield of AECG monitoring is
relatively low. The majority of such patients have no
symptoms during ambulatory recording, and further evalu-
ation is necessary. However, because of the severity of the
symptoms, such testing is usually warranted. Nevertheless,
the rhythm during asymptomatic periods may be useful. For
example, a patient may have syncope only during severe
bradycardia. An ambulatory ECG that shows intermittent
episodes of asymptomatic bradycardia may suggest the
diagnosis and prompt further evaluation. One study (23)
evaluated the utility of repeated 24-hour ambulatory record-
ing on 3 separate occasions. The first 24-hour recording
exhibited a major abnormality in 15% of the patients. The
additive yield was 11% on the second and 4.2% on the third
sequential recordings. Factors that identified a useful re-
cording were advanced age, male sex, history of heart
disease, and initial rhythm other than normal sinus. When
continuous AECG monitoring is not useful, intermittent
recorders (both patient-applied and loop) add incremental
value to continuous recording. Furthermore, the memory
capability of previously implanted pacemakers and ICDs
can add diagnostic value.
Insufficient data exist regarding near syncope or dizziness
alone to estimate the sensitivity and specificity of AECG
recording for these conditions (12).
2. Palpitation. The yield of ambulatory monitoring that
captures an episode of palpitation (Table 4) is higher than
the yield for patients with syncope, probably because the
frequency of occurrence of palpitation is higher than the
occurrence of syncopal episodes, though findings are likely
to be more variable in patients with palpitation (58,71).
Palpitation accounts for 31% to 43% of indications for
outpatient AECG monitoring (68,69). Furthermore, in
patients with preexisting palpitation, asymptomatic episodes
of supraventricular arrhythmias are more common than
symptomatic episodes (80,81).
3. Other Symptoms. Other cardiac symptoms such as
intermittent shortness of breath, unexplained chest pain,
episodic fatigue, or diaphoresis might be related to cardiac
arrhythmias. AECG monitoring may be indicated for these
symptoms. Other conditions such as stroke or transient
ischemic attack may be associated with cardiac arrhythmias,
which could be detected by AECG (79,82).
Indications for AECG to Assess Symptoms Possibly
Related to Rhythm Disturbances
Class I
1. Patients with unexplained syncope, near syncope,
or episodic dizziness in whom the cause is not
obvious
Table 3. Yield of AECG Monitoring for Syncope*
Author (Reference)
No. of
Patients
Symptoms at
Presentation
Symptoms During
Monitoring, n (%)
No Symptoms During
Monitoring, n (%)
Arrhythmia No Arrhythmia Arrhythmia No Arrhythmia
Bass et al (23) 95 Syncope 1 (1) 19 (20) 2 (26) 50 (53)
Kapoor et al (59) 249 Syncope 15 (6) 55 (22) 42 (17) 137 (55)
Gibson and Heitzman (66) 1512 Syncope, near
syncope, dizziness
30 (2) 225 (15) 15 (10) 1101 (73)
Kala et al (67) 107 Syncope, dizziness 8 (7) 8 (7) 17 (16) 74 (69)
Zeldis et al (68) 74 Syncope, dizziness 10 (14) 18 (24) . . . . . .
Clark et al (69) 98 Syncope, dizziness 3 (3) 39 (39) 41 (41) 17 (17)
Boudoulas et al (78) 119 Syncope, dizziness 31 (26) 15 (13) 32 (27) 41 (34)
Jonas et al (79) 358 Syncope, dizziness 14 (4) . . . 57 (16) 286 (80)
All studies† 2612 112 (4) 379 (15) 369 (14) 1706 (65)
*From Linzer et al (65), with permission.
†Totals do not add up to 100% because information was missing from 2 studies.
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2. Patients with unexplained recurrent palpitation
Class IIb
1. Patients with episodic shortness of breath, chest
pain, or fatigue that is not otherwise explained
2. Patients with neurological events when transient
atrial fibrillation or flutter is suspected
3. Patients with symptoms such as syncope, near
syncope, episodic dizziness, or palpitation in whom
a probable cause other than an arrhythmia has been
identified but in whom symptoms persist despite
treatment of this other cause
Class III
1. Patients with symptoms such as syncope, near
syncope, episodic dizziness, or palpitation in whom
other causes have been identified by history, phys-
ical examination, or laboratory tests
2. Patients with cerebrovascular accidents, without
other evidence of arrhythmia
V. ASSESSMENT OF RISK IN PATIENTS WITHOUT
SYMPTOMS OF ARRHYTHMIAS
AECG monitoring has been increasingly used to identify
patients, both with and without symptoms, at risk for
arrhythmias. The selection of patients for different types of
devices and duration of recording is similar to that previ-
ously discussed in Sections II and III.
A. After Myocardial Infarction
Myocardial infarction (MI) survivors are at an increased
risk of sudden death, with the incidence highest in the first
year after infarction (84,85). The major causes of sudden
death are ventricular tachycardia and ventricular fibrillation.
The risk of developing an arrhythmic event has declined
with the increasing use of thrombolytic agents and coronary
revascularization (86–88). Currently, the 1-year risk of
developing a malignant arrhythmia in an MI survivor after
hospital discharge is 5% or less (86,87,89–91). The goal in
risk-stratifying patients is to identify a population of pa-
tients at high risk of developing an arrhythmic event and
reduce such events with an intervention. Ideally, these
patients would be identified by a test or combination of tests
with a high sensitivity and a very high positive predictive
accuracy, so that as few patients as possible are unnecessarily
exposed to treatment.
AECG monitoring usually is performed over a 24-hour
period before hospital discharge. Some studies suggest that
4 hours of AECG monitoring provides as much informa-
tion as 24 hours (92,93). In many studies, AECG monitor-
ing was performed at least 6 and often approximately 10
days after the acute MI (Table 5). Frequent premature
ventricular contractions (PVCs) (eg, 10 per hour) and
high-grade ventricular ectopy (eg, repetitive PVCs, multi-
form PVCs, ventricular tachycardia) after MI have beenTa
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associated with a higher mortality rate among MI survivors
(86,89–91,94–100). However, once patients have at least 6
PVCs per hour, the risk of an arrhythmic event does not
increase with more frequent PVCs (101). The association
between ventricular arrhythmias and adverse cardiac events
has been demonstrated primarily in men (102,103).
The positive predictive value (PPV) of ventricular ectopy
in most of these studies for an arrhythmic event has been
low, ranging from 5% to 15%. The sensitivity of ventricular
ectopy can be increased by combining it with decreased LV
function. The PPV increases to 15% to 34% for an arrhyth-
mic event if one combines AECG monitoring with an
assessment of LV function (90,94,104,105).
Low values for high frequency measures of HRV (eg,
rMSSD or pNN50) and baroreflex sensitivity (BRS) indi-
cate decreased vagal modulation of R-R intervals (45,106).
The specific mechanism by which HRV and BRS are
reduced after MI remains unknown, but they decrease in
patients early after MI (reaching a nadir after 2 to 3 weeks)
and then increase back to normal levels by 6 to 12 months.
Decreased HRV and BRS are independent predictors of
increased mortality rates, including sudden death, in pa-
tients after MI (89,95,100,104,106–108) (Table 6). How-
ever, the predictive value of both HRV and BRS after MI,
although statistically significant, is poor when used alone.
HRV may be determined from traditional 24-hour
AECG monitoring or from shorter-duration monitoring.
Although HRV measured from short-term recordings is
depressed in patients at high risk, the predictive value
increases with length of recording (109,110). Shorter-term
recordings have lower specificity compared with 24-hour
recordings in predicting patients at high risk, and there may
be diurnal variation in HRV in some patients (110–112).
The optimal time-domain parameters for analysis of risk are
SDNN and HRV triangular index. High-risk patients have
either an SDNN ,70 ms, HRV triangular index ,15, or
BRS ,3 ms/mm Hg. These patients may also be identified
by examining power in the ultra-low-frequency range.
Although each of these tests has a predictive value
independent of other well-established risk factors after MI,
such as depressed LV function, their overall value is low.
Combining these tests with each other and other clinical
factors markedly improves their PPVs. As seen in Table 7,
a variety of combinations has been used; however, it is not
clear which is the best combination to use at the present
time. The prognostic capability of these tests is reviewed in
Table 8.
The combined use of AECG monitoring, LV function,
and signal-averaged ECG has improved the positive pre-
dictive accuracy of risk stratification (sensitivity 80% and
specificity 89%) (97). Also, Farrell et al (89) showed that
reduced HRV and the presence of late potentials on
signal-averaged ECG were a strong predictor of arrhythmic
events after MI. These findings were present in only 10% of
their patients, and even in this group the PPV was limited
to 33%. The ATRAMI (Autonomic Tone and ReflexesTa
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after Myocardial Infarction) study also examined the prac-
tice of combining multiple markers of HRV. It showed that
the presence of both a reduced HRV and reduced BRS
increased a patient’s relative risk of cardiac events 7-fold, but
these 2 findings were present in only 5% of the patients
(106). Adding more clinical findings (eg, ejection fraction)
and demographic features (eg, age) further improves the
ability to identify high-risk subgroups, but these patients
represent very small proportions of the population (106).
AECG is not needed in asymptomatic post-MI patients
who have an ejection fraction of $40% (100) because
malignant arrhythmias occur infrequently in such patients.
Long-term survivors of MI with reduced LV function
remain at increased risk of dying from a cardiovascular
event. However, the primary reason for patients to undergo
AECG monitoring is to identify those with a poorer
prognosis and ultimately to improve outcomes through
active treatment. Recently, the Multicenter Automatic De-
fibrillator Implantation Trial (MADIT) showed that ICD
therapy reduces mortality rates by approximately 50% in MI
survivors who had a reduced LV ejection fraction (#35%),
who had at least 1 asymptomatic nonsustained ventricular
arrhythmia, and in whom ventricular fibrillation or sus-
tained ventricular tachycardia was reproducibly induced
during electrophysiological testing and not suppressed by
use of intravenous procainamide (113). Unfortunately, the
study does not provide data on how many patients after MI
had this combination of findings nor how many were
identified as having asymptomatic ventricular arrhythmias
detected only by AECG.
Similarly, a recent meta-analysis examined whether ami-
odarone prevented sudden death in a series of randomized
controlled trials (114). Amiodarone reduced the incidence
of sudden death, cardiac death, and total mortality rates in
these trials. However, the patient populations were hetero-
geneous, and only two thirds of the trials required ventric-
ular ectopy for study entry. In addition, survival for patients
who received amiodarone was only different from the usual
and active care groups; there was no significant difference
when compared with placebo (ie, the alternative treatment
may have been harmful, and this could have artificially
increased the effect of amiodarone). Thus the role of AECG
in identifying this population remains unanswered.
B. Congestive Heart Failure
Patients with congestive heart failure (CHF), whether
caused by an ischemic cardiomyopathy or an idiopathic
dilated cardiomyopathy, often have complex ventricular
ectopy and a high mortality rate (115,116). There were
conflicting findings in a series of small studies, with some
suggesting a relation between ventricular arrhythmias and
death (117–119) and others finding no such relation
(115,116,120). Several more recent studies with larger
populations have found that ventricular arrhythmias (eg,
ventricular tachycardia, nonsustained ventricular tachycar-
dia) are sensitive but not specific markers of death (121,122)
and sudden death (122) (Table 9). Despite identifying a
population with an increased relative risk of an adverse
event, these tests are either not sensitive or have low PPVs.
HRV is decreased in patients with CHF (123,124). This
decrease is improved with the use of angiotensin-converting
enzyme inhibitor treatment (125,126). However, there are
divergent results with respect to the association between
HRV and arrhythmic events (127–132). In addition, there
is no evidence that reducing the frequency of these arrhyth-
mias or increasing the HRV with medications can signifi-
cantly reduce the incidence of total death or sudden death in
patients with severe CHF (114). Thus there is not sufficient
evidence to support the routine use of AECG or HRV in
patients with CHF or dilated cardiomyopathies.
Table 6. Sensitivity and Specificity of HRV for Predicting Arrhythmic Events After MI
Author (Reference)
No. of
Patients Criteria
Sensitivity,
%
Specificity,
%
PPV,
%
NPV,
% End Points
Kleiger et al (95) 808 HRV ,50 ms* 34 88 34 88 All-cause death
Farrell et al (89) 416 HRV triangular index ,20† 92 77 17 77 Arrhythmic event
Mean R-R interval ,750 ms 67 72 13 97
Odemuyiwa et al (107) 385 HRV triangular index #30† 75 76 Arrhythmic event
Bigger et al (104) 715 ULF 28 93 41 All-cause death
VLF 30 92 39
ULF1VLF 20 96 48
Pedretti et al (100) 294 HRV triangular index #29† 89 68 15 99 Arrhythmic event
La Rovere et al (106) 1170 HRV ,70 ms* 39 85 10 97 Arrhythmic event†
and cardiac death
1182 BRS ,3.0 ms/mm Hg 35 86 10 97 Arrhythmic event‡
and cardiac death
NPV indicates negative predictive value; ULF, ultra-low-frequency power; and VLF, very-low-frequency power.
*HRV calculated using SDNN (standard deviation of all NN intervals).
†Total number of all NN intervals divided by the height of the histogram of all NN intervals measured on a discrete scale with bins of 7.8125 ms (1/128 seconds).
‡Arrhythmic event defined as nonfatal cardiac arrest caused by documented ventricular fibrillation.
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C. Hypertrophic Cardiomyopathy
Sudden death and syncope are common among patients
with hypertrophic cardiomyopathy. The exact relation be-
tween ventricular arrhythmias or HRV and outcomes for
patients with hypertrophic cardiomyopathy remains open to
question. Three studies show that there is some association
between ventricular arrhythmias and adverse events, but
they differ on the nature of the association (133–135).
Another study found no association between HRV indexes
and adverse events (136). Although AECG monitoring may
add to the prognostic information provided by known risk
factors for patients with hypertrophic cardiomyopathy,
treatment of these ventricular arrhythmias has not consis-
tently been shown to increase life expectancy. Hence the
specific role of AECG in the day-to-day treatment of these
patients remains unclear.
D. Valvular Heart Disease
A few studies have examined the relation between valvu-
lar heart disease and HRV or ventricular ectopy. At the
present time, the presence of mitral valve prolapse (137),
chronic mitral regurgitation (138), or aortic valve prosthesis
(139) without other symptoms does not establish the need
for AECG monitoring nor for assessing HRV.
E. Diabetic Neuropathy
Diabetes is associated with diffuse degeneration of sym-
pathetic and parasympathetic small nerve fibers. More than
half the patients with symptomatic diabetic neuropathy will
die within 5 years (140). Because heart rate and rhythm are
under the control of the autonomic nervous system, several
groups have studied the relation between HRV and diabetic
neuropathy. High-frequency measures of HRV can detect
small changes in cardiac autonomic function in diabetic
subjects (141–143) and can distinguish diabetic subjects
with neuropathy from those without neuropathy (144).
Although these tests are reliable and sensitive for cardiac
parasympathetic function, their clinical utility is limited for
2 reasons. First, large numbers of diabetic subjects have
reduced HRV (142). Second, there is no evidence that early
identification of subclinical diabetic neuropathy will lead to
improved patient outcomes. In a report on the natural
history of diabetic neuropathy, more than half the deaths
were due to kidney failure and not cardiac arrhythmias
(140). Thus, routine HRV testing is not indicated at this
time.
F. Hemodialysis Patients
Patients with kidney failure who are receiving hemodial-
ysis are at increased risk of dying from a cardiovascular event
and have an increase in ventricular ectopy during dialysis
(145). In a minority of these patients, significant ventricular
arrhythmias develop (146). Those most at risk of having an
abnormal AECG recording are patients with known coro-
nary artery or peripheral vascular disease (147). Patients
with Lown grade 3 or higher arrhythmia (148) have
decreased survival compared with patients without ventric-
ular ectopy (147). Whether this prognostic information
justifies performing AECG monitoring on these patients is
unknown.
G. Systemic Hypertension
Systemic hypertension is the most common cause of LV
hypertrophy (149). Hypertensive patients with either ECG
(150) or echocardiographic (151–153) criteria of LV hyper-
trophy have an increased incidence of complex ventricular
arrhythmias. There is an increased risk of ventricular ar-
rhythmias, MI, and sudden death in patients with LV
hypertrophy (154,155). AECG monitoring of asymptom-
atic patients with LV hypertrophy is of uncertain value
because those patients with complex or frequent arrhyth-
mias have only a marginally significant risk of dying after
adjusting for age, sex, and other clinical factors (OR 1.62;
95% CI 0.98–2.68) (156).
Table 9. Sensitivity and Specificity of AECG and HRV for Predicting Arrhythmic Events in Patients With CHF
Author (Reference)
No. of
Patients Criteria
Sensitivity,
%
Specificity,
%
PPV,
%
NPV,
%
Adjusted RR
(95% CI) End Points
Doval et al (122) 516 NSVT 58 70 24 91 2.6 (1.6–4.1) Sudden death
295 NSVT or couplets 89 42 21 96 2.9 (1.1–7.6) Sudden death
516 NSVT 45 73 50 69 1.6 (1.2–2.2) Total death
295 NSVT or couplet 76 32 51 74 10.1 (1.9–52.7) Total death
Szabo et al (121)* 204 VT 60 72 38 86 Cardiac death
Pelliccia et al (119) 104 Lown class $4 31 88 58 72 Cardiac death
Ponikowski et al (130) 102 SDNN ,100 79 67 37 93 Total death
Huang et al (115) 35 NSVT 50 65 5 93 Sudden death
Igekawa (120)* 33 NSVT 71 81 50 91 Sudden death
$100 PVCs/h 71 81 45 91
NSVT1$100 PVCs/h 57 96 80 89
Holmes et al (117) 31 Lown class $4 7 53 11 41 Cardiac death
NPV indicates negative predictive value; NSVT, nonsustained ventricular tachycardia; VT, ventricular tachycardia.
*Calculations are derived from figures in published articles.
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H. Preoperative and Postoperative Patients
AECG monitoring has been used in the preoperative
evaluation of patients and after a variety of cardiac opera-
tions. No association has been found between preoperative
ventricular arrhythmias and postoperative events when used
before surgery in high-risk patients undergoing noncardiac
surgery who have no myocardial ischemia and are without
severe LV dysfunction (157). Similarly, no association has
been found between the occurrence of complex ventricular
ectopy after coronary artery bypass surgery and death after
controlling for other clinical factors (158). Finally, although
AECG is occasionally recommended for preoperative test-
ing in patients with bundle-branch block, there are no data
supporting this use.
I. Screening in Other Patients
There are conflicting results concerning the relation
between asymptomatic ventricular arrhythmias and out-
comes in the elderly, patients with obstructive lung disease,
and others. Some studies demonstrate an increased risk and
other studies show no difference in risk (159–164). AECG
monitoring was not of value in patients who had sustained
a myocardial contusion (165) nor in those with sleep apnea
(166,167). Therefore there is insufficient evidence to sup-
port routine use of AECG monitoring in these patient
populations.
J. Monitoring Pharmacological Management
Several medications used in the treatment of patients
with cardiac conditions affect either directly or indirectly the
autonomic nervous system. Analysis of R-R variability may
provide a tool for understanding these various pharmaco-
logical manipulations (168–173). To date, the prognostic
implications of the noted alterations are unknown. In drug
development, analysis of R-R variability may provide in-
sights into mechanisms of action. Future studies should
include outcomes research.
K. Summary
Although arrhythmia detection and HRV analyses each
provide some incremental information that may be useful in
identifying patients without symptoms of arrhythmias at
increased risk of future cardiac events, their overall value is
limited at the present time because of their relatively low
sensitivity and PPV. Combining AECG, HRV, signal-
averaged ECG, and LV function improves the quality of the
information provided, but the best way to combine data
from these different tests remains elusive. Three groups may
benefit from either AECG or HRV monitoring: patients
with idiopathic hypertrophic cardiomyopathy, patients with
CHF, and post-MI survivors with reduced ejection fraction.
However, these tests cannot be recommended for routine
use in any other population at the present time.
Indications for AECG Arrhythmia Detection to Assess
Risk for Future Cardiac Events in Patients Without
Symptoms From Arrhythmia
Class I
None
Class IIb
1. Post-MI patients with LV dysfunction
2. Patients with CHF
3. Patients with idiopathic hypertrophic cardiomyop-
athy
Class III
1. Patients who have sustained myocardial contusion
2. Systemic hypertensive patients with LV hypertro-
phy
3. Post-MI patients with normal LV function
4. Preoperative arrhythmia evaluation of patients for
noncardiac surgery
5. Patients with sleep apnea
6. Patients with valvular heart disease
Indications for Measurement of HRV to Assess Risk
for Future Cardiac Events in Patients Without
Symptoms From Arrhythmia
Class I
None
Class IIb
1. Post-MI patients with LV dysfunction
2. Patients with CHF
3. Patients with idiopathic hypertrophic cardiomyop-
athy
Class III
1. Post-MI patients with normal LV function
2. Diabetic subjects to evaluate for diabetic neuropa-
thy
3. Patients with rhythm disturbances that preclude
HRV analysis (ie, atrial fibrillation)
VI. EFFICACY OF ANTIARRHYTHMIC THERAPY
AECG has been widely used to assess the effects of
antiarrhythmic therapy. The technique is noninvasive, pro-
vides quantitative data, and permits correlation of symptoms
with ECG phenomena. However, limitations of AECG as
a therapeutic guide affect its usefulness. These limitations
include significant day-to-day variability in the frequency
and type of arrhythmias in many patients, a lack of corre-
lation between arrhythmia suppression after an intervention
and subsequent outcome, uncertain guidelines for the de-
gree of suppression required to demonstrate an effect, either
statistical or clinical, and an absence of quantifiable spon-
taneous asymptomatic arrhythmias between episodes in
many patients with a documented history of life-threatening
arrhythmias (12).
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The basis for the use of AECG has been the hypothesis
that a reduction from baseline levels in arrhythmia fre-
quency or type during serial monitoring after institution of
therapy will correlate with an improved long-term clinical
response. The majority of placebo-controlled, randomized
data concerning this hypothesis has been generated in
patients with asymptomatic ventricular ectopy. Uncon-
trolled data and data comparing AECG with electrophysi-
ological studies are available in patients with prior sustained
ventricular tachycardia or ventricular fibrillation. Because of
the limited day-to-day occurrence of supraventricular ar-
rhythmias and the uncertain significance of asymptomatic
nonsustained atrial ectopy, quantitative analysis of long-
term AECG recordings has not been widely used to guide
therapy of supraventricular arrhythmias. However, intermit-
tent monitoring to confirm the presence of an arrhythmia
during symptoms and to document arrhythmia-free inter-
vals has become a standard approach for evaluating the
effects of antiarrhythmic therapy in patients with supraven-
tricular arrhythmias (177). The AECG also may be used to
monitor the effects of atrioventricular (AV) nodal blocking
drugs on heart rate in patients with atrial arrhythmias.
A number of authors have examined the day-to-day
variability in the frequency and type of arrhythmia detected
in various patient populations (13–20,178–180). As shown
in Table 10, short-term reproducibility of data between
recordings was poor, and large reductions (63% to 95%) in
arrhythmia frequency would be required to ensure that the
change was due to an antiarrhythmic effect of any interven-
tion. Long-term reproducibility of ventricular arrhythmia
frequency and types is limited as well (17,21,181–184).
The Cardiac Arrhythmia Suppression Trial (CAST)
tested the hypothesis that suppression of spontaneous ec-
topy by an antiarrhythmic drug would reduce mortality rates
in patients with asymptomatic ventricular arrhythmias after
MI (185–189). The active drugs used in the study were
encainide, flecainide, and moricizine. In the initial design,
all patients were assigned to active drug treatment, and
suppression of spontaneous ectopy during a titration phase
was monitored. Patients who did not manifest suppression
were not randomly assigned and had a more than 2-fold
higher mortality rate than did the patients whose arrhyth-
mias were suppressed and who were randomly assigned to
placebo (180,185–188). A higher mortality rate during
follow-up was observed in those patients who had suppres-
sion and then received chronic encainide or flecainide
therapy as opposed to placebo. After this observation, the
trial design was altered and the study continued with
moricizine as the only active agent. A higher mortality rate
during a placebo-controlled drug titration with moricizine
was observed, and there was no indication of benefit with
long-term therapy (187).
The data from CAST led to a revision of many concepts
concerning methods for guiding antiarrhythmic drug ther-
apy in asymptomatic patients. It was seen that suppression
of spontaneous asymptomatic or mildly symptomatic ven-
tricular ectopy with an antiarrhythmic drug might not only
be ineffective but actually harmful. Thus therapy in such
patients with Class I antiarrhythmic drugs is currently not
recommended. The data also gave rise to the concept of the
“healthy responder” (ie, patients who respond to an inter-
vention, in this case AECG-guided drug therapy, may have
a different prognosis than those who do not) (190). This
observation influences the interpretation of data from other
studies that do not include an untreated control group.
Controlled data from mortality trials with AECG as a
guide to therapy with other antiarrhythmic agents are not
available, but many trials have evaluated the unguided use of
Class Ia, Class Ib, and selected Class III antiarrhythmic
agents (191,192). These trials have demonstrated either no
benefit or an adverse effect with antiarrhythmic drug ther-
apy. Studies with empiric use of amiodarone have been
inconsistent, with some studies showing a benefit (193–196)
and others showing no significant change in mortality rates
(88,197,198). In one trial (198), amiodarone produced a
significant reduction in arrhythmia frequency but had no
effect on mortality rate. It has not been demonstrated that
amiodarone therapy guided by responses during serial
AECG would improve these results.
Placebo-controlled trials of antiarrhythmic interventions
in patients with sustained life-threatening ventricular ar-
rhythmias are problematic. One favorable early report
showed improvements in arrhythmia-free survival in pa-
tients who met certain criteria for a drug response during
serial AECG (199,200). It is not possible to estimate the
effects of the “healthy responder” phenomenon on these
observations.
AECG has been compared with serial electrophysiolog-
ical studies in 2 randomized trials in patients with prior
sustained ventricular arrhythmias. A small study by Mitchell
et al (201) suggested that an electrophysiological study–
based approach was superior, whereas the much larger
Electrophysiologic Study Versus Electrocardiographic
Monitoring (ESVEM) study showed no difference in out-
come with the use of the 2 approaches to select initial
therapy (202). Both of these studies, however, had many
important limitations, and firm conclusions about the rela-
tive value of the 2 approaches remain uncertain. Of note, the
ESVEM trial did not include amiodarone, the agent most
commonly selected in patients with serious arrhythmias in
several recently completed antiarrhythmic trials (113,203).
It is also important to note that not all patients with a
history of sustained ventricular tachycardia will manifest
high-frequency or complex ventricular ectopy. Swerdlow
and Peterson (204) found, in a cohort of patients with CAD
and sustained ventricular arrhythmias, that 76% had spon-
taneous ventricular arrhythmias suitable for drug assessment
on a 24-hour AECG. In the 2 randomized trials mentioned
above that compared serial AECG versus electrophysiolog-
ical testing for selecting drug therapy, Mitchell et al (201)
and the ESVEM group (202) found that 32% and 17%,
respectively, of patients approached had insufficient sponta-
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neous ectopy to enter the trial. The former single-center
trial study screened consecutive patients at that site who
presented with a symptomatic ventricular arrhythmia and
required $30 PVCs per hour for enrollment. ESVEM, a
multicenter study performed at 14 sites, did not always
obtain an AECG to quantify ventricular ectopy in patients
with consecutive ventricular arrhythmia at the sites and
required in the monitored patients only 10 PVCs per hour
for enrollment.
It should be noted that the ICD offers an alternate
strategy for treatment of patients with life-threatening
ventricular arrhythmias. Many current-generation ICDs
store event electrograms for retrieval, and ambulatory mon-
itoring is now rarely required to assess ICD utility.
Very few patients with sustained supraventricular ar-
rhythmias have episodes on a daily basis. Guidelines for
assessing therapy for supraventricular arrhythmias based on
a quantitative analysis of the frequency or pattern of
asymptomatic atrial ectopic beats are not available. How-
ever, protocols for rigorous assessment of antiarrhythmic
drug efficacy with intermittent monitoring have been devel-
oped and validated. In these protocols, patients are asked to
record and transmit ECG data from intermittent recording
monitors to document the presence of arrhythmias during
symptoms (205). Once a baseline frequency has been
established, therapy is begun and the “arrhythmia-free”
interval is used as a measure of drug effect. This type of
protocol is now accepted as the standard for an antiarrhyth-
mic drug development program for supraventricular ar-
rhythmias because it provides a statistically valid measure of
drug effect on symptomatic arrhythmias in a given popula-
tion (205,206). Asymptomatic arrhythmias, also commonly
present, would not be detected unless long-term recordings
or periodic surveillance transmissions were also obtained
(80). Use of a similar protocol in routine practice is not
common, but the use of intermittent recordings in a
nonquantitative manner may be clinically useful in patients
with recurrent symptoms. AECG recordings are also of
value for documenting control of the ventricular rate in
patients with continuous atrial arrhythmias because they
provide data on the heart rate during the patient’s typical
daily activities.
The concept of proarrhythmia includes both provocation
of new arrhythmia and exacerbation of preexisting arrhyth-
mia as a result of antiarrhythmic drug therapy (207,208).
Proarrhythmia may occur early or late during the course of
therapy. In previously asymptomatic patients with ventric-
ular ectopy, proarrhythmia is usually defined as an increase
in frequency of ventricular premature depolarizations or of
runs of ventricular tachycardia. The increase needed to
differentiate proarrhythmia from day-to-day variability may
be estimated statistically on the basis of baseline arrhythmia
frequency (207,208). In CAST, patients who manifest an
early increase in ventricular premature depolarization had a
higher mortality rate when treated with placebo than did
those without this finding (209). Increased QT intervals,
sinus node dysfunction, and new or worsened AV conduc-
tion abnormalities are other types of asymptomatic but still
clinically relevant proarrhythmia that may be detected by
AECG in patients receiving antiarrhythmic drug therapy.
Indications for AECG to Assess Antiarrhythmic
Therapy
Class I
1. To assess antiarrhythmic drug response in individ-
uals in whom baseline frequency of arrhythmia has
been well characterized as reproducible and of
sufficient frequency to permit analysis
Class IIa
1. To detect proarrhythmic responses to antiarrhyth-
mic therapy in high-risk patients
Class IIb
1. To assess rate control during atrial fibrillation
2. To document recurrent symptomatic or asymptom-
atic nonsustained arrhythmias during therapy in the
outpatient setting
Class III
None
VII. ASSESSMENT OF PACEMAKER AND ICD
FUNCTION
Over the last 10 years, the function and diagnostic capabil-
ities of pacemakers and ICDs have become more complex
(210–215). As a result, trouble-shooting device function
and determining optimal device programming has become
more challenging. AECG is useful in correlating frequent
symptoms with cardiac rhythm abnormalities and thereby
can aid in evaluating symptomatic patients for pacemaker
implantation. Guidelines have been previously set forth
describing appropriate indications for permanent pacemaker
implantation (216), and AECG is useful in both document-
ing the presence of significant bradyarrhythmias and estab-
lishing whether or not an association exists between a
patient’s symptoms and the presence of cardiac arrhythmia.
Once a device is implanted, AECG is useful in assessing
postoperative device function as well as in guiding appro-
priate programming of enhanced features such as rate
responsivity and automatic mode switching. AECG can
sometimes be a useful adjunct to continuous telemetric
observation after pacemaker implantation in assessing de-
vice function and thereby aid in determining the need for
either device reprogramming or operative intervention
(217). Present-generation pacemakers are capable of limited
AECG monitoring function, which at the present time is
not capable of entirely supplanting conventional AECG.
They accomplish this with various algorithms by which
complexes are classified according to whether or not they are
preceded by atrial sensed or paced events (218). Tabular
data can then be obtained from pacemaker memory at the
time of follow-up interrogation, which quantifies how many
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or what percentage of atrial and ventricular events were
either sensed or paced, including a separate quantification of
sensed ventricular events without preceding atrial activity.
Although these algorithms were primarily designed to
profile pacemaker activity to optimize device programming
including AV delay, rate responsivity, and upper and lower
rate limits, these data can be used to broadly determine the
frequency of ventricular ectopy. The resolution of the data,
however, usually does not allow for minute-to-minute
counts or detailed characterization of repetitive ectopy (ie,
rate, duration, or morphology of ventricular tachycardia).
Because present devices do not provide electrogram confir-
mation of these counts, the accuracy of the tabulated data
provided by these devices depends on accurate sensing and
pacing function. Undersensing or oversensing of cardiac
events or events occurring during blanking or refractory
periods will result in inaccurate counts.
When compared with pacemakers, present-generation
ICDs are capable of more detailed electrogram recording of
events precipitating device activation. These recordings,
however, are made over a significantly more limited time
duration (usually on the order of 5 to 30 seconds per event,
up to approximately 5 to 10 minutes of total recording
duration). Although these recordings provide more com-
plete disclosure and allow for direct physician review, the
limited recording duration and absence of a surface ECG
with which to provide data regarding QRS morphology are
substantial limitations. Currently under development are
devices capable of AECG while acquiring on-line telemetric
data from an implanted device (219). This data link can
then be used to correlate device function with a recorded
ECG signal, thus allowing for more detailed analysis of
pacemaker or ICD function during a more prolonged time
period.
During outpatient follow-up of patients undergoing de-
vice implantation, AECG is useful in correlating intermit-
tent symptoms with device activity (76,220). Pacing thresh-
olds in the atrium and ventricle evolve after lead
implantation, and abnormalities of sensing and capture can
be documented during chronic follow-up. Device longevity
can be maximized with appropriate programming of output
parameters, and AECG can be useful in assessing device
function after such reprogramming.
Patients having undergone ICD implantation for the
management of ventricular arrhythmias often have ICD
shock therapy during follow-up. AECG can be a useful
adjunct in establishing the appropriateness of such therapy
(221,222). The efficacy of adjunctive pharmacological ther-
apy in suppressing spontaneous arrhythmias in an attempt
to minimize the frequency of device activation also can be
assessed by this technique. Although present-generation
ICDs are capable of storing electrograms of the spontaneous
rhythm resulting in device activation, differentiating su-
praventricular from ventricular arrhythmias solely on the
basis of these recordings can be difficult (222). At the
present time, AECG remains a useful adjunct in fine tuning
device function (222), including ensuring that there is no
overlap in programmed tachycardia detection rate and the
maximum heart rate achieved during daily activity.
Technology remains a moving target (223,224). Devices
capable of more robust telemetry capabilities are already
under development, and although it is conceivable that
future devices implanted for the management of tachy-
arrhythmias and bradyarrhythmias may be totally self-
sufficient in their diagnostic function, at the present time
AECG remains a useful adjunct in the evaluation of
pacemaker and ICD function.
Indications for AECG to Assess Pacemaker and ICD
Function
Class I
1. Evaluation of frequent symptoms of palpitation,
syncope, or near syncope to assess device function
so as to exclude myopotential inhibition and
pacemaker-mediated tachycardia and to assist in
the programming of enhanced features such as rate
responsivity and automatic mode switching
2. Evaluation of suspected component failure or mal-
function when device interrogation is not definitive
in establishing a diagnosis
3. To assess the response to adjunctive pharmacolog-
ical therapy in patients receiving ICD therapy
Class IIb
1. Evaluation of immediate postoperative pacemaker
function after pacemaker or ICD implantation as
an alternative or adjunct to continuous telemetric
monitoring
2. Evaluation of the rate of supraventricular arrhyth-
mias in patients with implanted defibrillators
Class III
1. Assessment of ICD/pacemaker malfunction when
device interrogation, ECG, or other available data
(chest radiography, etc) are sufficient to establish an
underlying cause/diagnosis
2. Routine follow-up in asymptomatic patients
VIII. MONITORING FOR MYOCARDIAL ISCHEMIA
A. General Considerations
During the past decade, AECG monitoring has been
extensively used for detection of myocardial ischemia. Al-
though in the past there were a number of technical
limitations that led to inadequate and unreliable evaluation
of ST-segment changes, with the recent advent of techno-
logical advancements it is now widely accepted that AECG
monitoring provides accurate and clinically meaningful
information about myocardial ischemia in patients with
coronary disease (225–230). A number of well-designed
clinical studies have evaluated the prevalence and prognostic
significance of myocardial ischemia detected by AECG
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monitoring (227,228,230–242). Most of these studies have
been conducted in patients with proven CAD, and there is
a relative paucity of data regarding the role of AECG
monitoring in asymptomatic subjects without known CAD
or peripheral vascular disease. There is presently no evidence
that AECG monitoring provides reliable information con-
cerning ischemia in asymptomatic subjects without known
CAD. Most of the studies that have evaluated the
relation between the findings obtained during exercise
testing and AECG monitoring demonstrated that ST-
segment changes indicative of myocardial ischemia dur-
ing AECG monitoring are relatively infrequent in pa-
tients with no evidence of ischemia during exercise
testing (243,244). However, in those with an ischemic
response during exercise testing, between 25% and 30%
of patients demonstrate ischemia during AECG moni-
toring. There is a significant correlation between the
magnitude of ischemia during the exercise tolerance test
and the frequency and duration of ischemia during
AECG monitoring (34). However, the strength of the
correlation is limited, indicating that the 2 tests are not
redundant to characterize coronary patients (34).
Unlike exercise testing, AECG monitoring has the dis-
tinct advantage of providing long-term monitoring for
myocardial ischemia in the outpatient setting while the
patient is performing usual daily activities (226,227), includ-
ing mental stress (245,246). AECG monitoring is also
useful for detection of myocardial ischemia in preoperative
risk stratification for patients who cannot exercise because of
physical disability, peripheral vascular disease, or advanced
lung disease. Ischemia monitoring by AECG can also be
helpful for evaluation of patients with anginal syndrome
with a negative exercise tolerance test if variant angina is
suspected. In addition, AECG monitoring for 24 to 48
hours can provide information regarding the circadian
pattern of myocardial ischemia as well as underlying
pathophysiological mechanisms responsible for the isch-
emic episodes during daily life. However, in symptomatic
patients, diagnostic accuracy is greater with exercise
testing (225).
AECG monitoring has the ability to provide comprehen-
sive evaluation of ischemia for a given patient. A number of
studies have documented that as much as 80% of ischemic
episodes that occur during daily life are not associated with
symptoms and would remain undiagnosed unless evaluated
by AECG monitoring (226–230). The results of some
studies have also demonstrated that episodes of asymptom-
atic ischemia during AECG monitoring can be frequently
detected in patients with angina pectoris who are receiv-
ing antianginal drug therapy and are considered to have
adequate control of symptoms (227–230). Such residual
ischemia, which would remain undetected without
AECG monitoring, has been documented in patients
with acute ischemic syndromes (unstable angina and after
MI) as well as in patients with stable CAD (227–236).
However, the clinical significance of such residual isch-
emia is unclear.
B. Prevalence and Predictive Value
The prevalence of myocardial ischemia detected by
AECG monitoring in patients with stable CAD and angina
pectoris ranges between 20% and 45%, with the highest
prevalence demonstrated in patients with more advanced
multivessel CAD (227–229,247). The available data from a
number of clinical studies have shown that between 30%
and 40% of patients with unstable angina and those with a
recent MI have evidence of myocardial ischemia during
AECG monitoring (230,239–242). A number of these
studies have emphasized that between 60% and 80% of
ischemic episodes detected by AECG monitoring are not
associated with symptoms (225–242). Because of lack of
symptoms and/or any patient discomfort, the detection of
myocardial ischemia by AECG monitoring would only be
of clinical significance if its presence was associated with
adverse prognosis. Indeed, a number of recent studies have
demonstrated that myocardial ischemia detected by AECG
monitoring identifies high-risk patients (230–242,248,249).
In patients with stable CAD, the results of studies (Table
10) have shown that the presence of ischemic episodes
detected by AECG monitoring is associated with a signif-
icantly greater risk of future coronary events and cardiac
death (231–238). The results of these studies have also
documented that ischemia detected during AECG moni-
toring is an independent predictor of clinical outcome
(when compared with several clinical predictors and ECG
variables) (231–238,249). In addition, some recent studies
have compared the prognostic value of data obtained during
exercise testing with the information available from AECG
monitoring, and the results of these studies have demon-
strated that ischemia detected by AECG monitoring can
provide prognostic information additional to that available
from established parameters obtained during exercise testing
(233,237,242).
AECG monitoring has also been used for preoperative
evaluation (Table 11) of patients with peripheral vascular
disease with no clinical evidence of CAD (250–259).
Between 10% and 40% of patients referred for major
vascular surgery have evidence of ischemia detected by
AECG monitoring (250–258). Although the independent
prognostic value of ischemia detected by AECG monitoring
for postoperative cardiac complications has been reported
(Table 12), more recent and larger studies have emphasized
that the presence of ischemia detected by AECG monitor-
ing in these patients also predicts a poor long-term prog-
nosis (250–259). However, on the basis of the available
data, when feasible, exercise testing alone or with an
imaging study remains the preferred test of choice for risk
stratification of patients with CAD or for preoperative
evaluation. For patients who cannot perform exercise,
AECG can be used for further evaluation.
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C. Role in Therapeutic Evaluation
During the past 5 to 7 years, AECG monitoring has been
used for the evaluation of efficacy of anti-ischemic therapy
in patients with CAD. The results of these studies have
revealed that because of day-to-day variability in ischemic
indexes, prolonged AECG monitoring for 48 hours is
usually necessary for therapeutic evaluation (26,260). A
number of studies have demonstrated that 48-hour AECG
monitoring performed at baseline and after institution of
therapy can provide reliable evaluation about the anti-isch-
emic efficacy of the drugs used in patients with CAD
(261–270). The results of these studies have provided
clinically meaningful information regarding differences in
the efficacy of various antianginal drugs and shed further
light on the pathophysiological mechanisms of actions of
various drugs. Data emerging from randomized clinical
trials (Table 13) suggest that suppression of myocardial
ischemia as evaluated by AECG monitoring may be asso-
ciated with improved outcome in patients with CAD
(264,268,271). However, large-scale, prospective, random-
ized clinical trials are needed to confirm these results before
definite recommendations can be made.
D. Limitations
It is important to note that ST-segment changes and
other repolarization abnormalities can occur for reasons
other than myocardial ischemia. These include hyperventi-
lation, hypertension, LV hypertrophy, LV dysfunction,
conduction abnormalities, postural changes, tachyarrhyth-
mias, preexcitation, sympathetic nervous system influences,
psychotropic drugs, antiarrhythmic drugs, digitalis, alter-
ations in drug levels, and electrolyte abnormalities. Al-
though the possibility of these false-positive changes should
not preclude the use of AECG monitoring for detection of
myocardial ischemia, it is critical to be aware of these
conditions while evaluating the predictive value of ST-
segment changes in a given patient. The other potential
limitation to the clinical use of AECG monitoring (espe-
cially for the evaluation of therapeutic interventions) is the
marked day-to-day variability in the frequency and duration
of ST depression and ischemic episodes, which makes it
difficult to assess the effects of therapy on ischemic indexes
recorded during AECG monitoring. This can be partially
rectified by performing prolonged (48- to 72-hour) AECG
monitoring recordings and assessing similar physical and
emotional activities performed by patients during serial
monitoring sessions. Because of these complex technical
requirements and diagnostic criteria, it is essential that the
use of AECG monitoring for detection of myocardial
ischemia be restricted to laboratories and personnel specif-
ically trained in this area.
Although ST-segment depression is the most frequently
encountered ECG sign of ischemia during AECG moni-
toring, it should be noted that occasionally one can encoun-
ter a period of ST-segment elevation (especially in patientsTa
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with variant angina or high-grade proximal stenoses) that is
indicative of transmural ischemia. Occasionally, changes in
T-wave polarity and morphology can be observed during
AECG monitoring; however, there are presently no data to
suggest that such changes are specific indicators of myocar-
dial ischemia.
Indications for AECG for Ischemia Monitoring
Class I
None
Class IIa
1. Patients with suspected variant angina
Class IIb
1. Evaluation of patients with chest pain who cannot
exercise
2. Preoperative evaluation for vascular surgery of pa-
tients who cannot exercise
3. Patients with known CAD and atypical chest pain
syndrome
Class III
1. Initial evaluation of chest pain patients who are
able to exercise
2. Routine screening of asymptomatic subjects
IX. PEDIATRIC PATIENTS
The purposes of AECG monitoring in pediatric patients
include 1) the evaluation of symptoms that may be arrhyth-
mia related; 2) risk assessment in patients with cardiovas-
cular disease, with or without symptoms of an arrhythmia;
and 3) the evaluation of cardiac rhythm after an intervention
such as drug therapy or device implantation. As in adult
patients, selection of the method of monitoring (ie, contin-
uous recording versus patient activated) is predicated on the
frequency and symptoms of the arrhythmia.
Table 13. Clinical Trials to Assess Effect of Anti-Ischemic Strategies on Prognostic Significance of Daily Life Ischemia
Author (Reference)
No. of
Patients End Points
Follow-Up,
y Event Rate by Treatment Group P
Pepine et al (264) 306 Death, MI, unstable angina,
worsening angina, or
revascularization
1 25% placebo
11% atenolol
0.001
Rogers et al (268) 558 Death, MI, revascularization,
hospital admission
1 32% angina-guided medical strategy
31% ischemia-guided medical strategy
18% revascularization strategy
0.003
Dargie et al (269) 682 Cardiac death, nonfatal MI,
and unstable angina
2 13% atenolol
11% nifedipine
8% combination
NS
Revascularization, worsening
angina
8% atenolol
9% nifedipine SR
3% combination
NS
Von Arnim (270) 520 Death, MI, unstable angina, or
revascularization
1 32% for non-100% responders
18% for 100% responders
0.008
33% for nifedipine
22% for bisoprolol
0.03
SR indicates sustained release.
Table 12. Predictive Value of Preoperative ST Monitoring by AECG for Perioperative Cardiac Events After Vascular Surgery
Author (Reference)
No. of
Patients
Patients With
Abnormal
Test
Criteria for
Abnormal
Test
Perioperative Events
Event Comments
Positive*
Test
Negative
Test
Raby et al (250) 176 18 A 10% (3/32) 1% (1/144) D, MI 24–48 h during ambulation
Pasternack et al (256) 200 39 A 9% (7/78) 2% (2/122) D, MI
Mangano et al (252) 144 18 A, B 4% (1/26) 4% (5/118) D, MI Immediately before surgery
Fleisher et al (253) 67 24 A, B 13% (2/16) 4% (2/51) D, MI Immediately before surgery
McPhail et al (255) 100 34 A 15% (5/34) 6% (4/66) D, MI
Kirwin et al (254) 96 9 A 11% (1/9) 16% (14/87) D, MI Definition of MI based on
enzymes only
Fleisher et al (257) 86 23 A, B 10% (2/20) 3% (2/66) D, MI Quantitative monitoring not
predictive
A indicates $1 mm ST-segment depression; B, $2 mm ST-segment elevation; and D, death.
*Positive predictive value for postoperative cardiac events.
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A. Evaluation of Symptoms
The use of AECG monitoring in pediatric patients for
the evaluation of symptoms possibly related to an arrhyth-
mia in the absence of heart disease has been the subject of
several reports (272–277). These symptoms include palpi-
tation, syncope or near syncope, and chest pain. Regarding
palpitation, a patient-activated recorder is generally recom-
mended because of the paroxysmal nature of the symptom.
An arrhythmia, usually supraventricular tachycardia, has
been reported to correlate with palpitation in 10% to 15% of
young patients, whereas ventricular ectopy or bradycardia is
demonstrated in another 2% to 5% (Table 14). By compar-
ison, sinus tachycardia is identified in nearly 50% of young
patients with symptoms of palpitation during ambulatory
monitoring, whereas 30% to 40% of patients have no
symptoms during monitoring. Therefore, one of the pri-
mary uses of AECG monitoring in pediatric patients is to
exclude an arrhythmia as the cause of palpitation.
The role of AECG monitoring in young patients with
transient neurological symptoms (syncope, near syncope, or
dizziness) in the absence of structural or functional heart
disease is limited (278). The intermittent nature of symp-
toms results in a low efficacy of 24 to 48 hours of continuous
ECG monitoring; conversely, temporary patient incapaci-
tation usually precludes patient-activated recording (279).
Continuous ECG monitoring is primarily indicated in
pediatric patients with exertional symptoms or those with
known heart disease, in whom the presence and significance
of an arrhythmia may be increased (278,280).
Chest pain may be evaluated by either continuous or
patient-activated ECG monitoring. However, a cardiac
cause of chest pain is identified in ,5% of pediatric patients
(281). Most AECG studies in pediatric patients have re-
ported no yield in the evaluation of chest pain (273,275,281).
Therefore the primary role of AECG monitoring in pedi-
atric patients with chest pain may be to exclude rather than
to diagnose a cardiac cause. However, although reassuring
to the physician, exclusion of an arrhythmia as the cause of
palpitation or chest pain may not alter the patient’s percep-
tion of a possible cardiovascular problem (282).
B. Evaluation of the Patient With Known Cardiovascular
Disease
AECG monitoring is commonly used in the periodic
evaluation of pediatric patients with heart disease, with or
without symptoms of an arrhythmia. The rationale for this
testing is the evolution of disease processes (such as long
QT syndromes or hypertrophic cardiomyopathies), growth
of patients and the need to adjust medication dosages, and
the progressive onset of late arrhythmias after surgery for
congenital heart defects.
The use of AECG monitoring for periodic evaluation of
patients with prior surgical treatment of congenital heart
disease must be based on consideration of the type of defect,
ventricular function, and risk of late postoperative arrhyth-
mias. For example, uncomplicated repairs of atrial or ven-
tricular septal defects are associated with a low incidence of
late postoperative arrhythmias (283). Conversely, complex
repairs or those with residual hemodynamic abnormalities
have a well-recognized incidence of late-onset atrial and
ventricular arrhythmias (284,285). Although the signifi-
cance of arrhythmias in these patients remains controversial,
high-grade ambulatory ventricular ectopy associated with
ventricular dysfunction does appear to identify patients at an
increased risk of late sudden death (286,287). Complex
arrhythmias detected in these patients by AECG may
indicate the need for further investigation, even in the
absence of overt symptoms (288).
Periodic AECG monitoring for young patients with
hypertrophic or dilated cardiomyopathies or the long QT
syndromes is recommended because of the progression of
these diseases and the need to adjust medication doses with
growth. The risk of sudden death with these diseases is
much greater in pediatric patients than adults, with sudden
death a first symptom in 9% to 15% of patients (289,290).
One primary role of AECG monitoring is to identify occult
Table 14. Yield of AECG Monitoring for Evaluation of Palpitation in Pediatric Patients With No Structural Heart Disease
Author (Reference)
No. of
Patients Method
Symptoms During Monitoring,
n (%)
No Symptoms
During Monitoring,†
No Arrhythmia, n
(%) Method
Mean No.
of Days of
MonitoringArrhythmia No Arrhythmia
Dick et al (272) 6 E 2 (33) 4 (67) 0 E
Fyfe et al (273) 41 E 9 (22) (8 SVT) 12 (29) 20 (49) E 75
Porter et al (274) 25 H 3 (12) 9 (36) 13 (52) H 1
Goldstein et al (275) 48 E 10 (21) (7 SVT) 15 (31) 23 (48) E 14–90
Karpawich et al (276) 37 E 10 (27) 27 (73) 0 E 30
Karpawich et al (276) 45 H 0 9 (20) 36 (80) H 1
Houyel et al (277) 201* E 24 (12) (23 SVT) 112 (56) 65 (32) E 85
Total 403 58 (14) 188 (47) 157 (39)
E indicates patient-activated event recorder; SVT, supraventricular tachycardia; and H, Holter (continuous 24-h recorder).
*Includes 25 patients with heart disease.
†Recognition of asymptomatic arrhythmias limited because event recorder would not be activated by patient.
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arrhythmias, which may indicate the need for reevaluation
of therapy in an asymptomatic patient. However, the
absence of an arrhythmia during monitoring does not
necessarily indicate a low risk of sudden death.
AECG monitoring has a limited role for establishing a
diagnosis of long QT syndrome in patients with borderline
QT prolongation. This is due to differences in sampling,
signal filtering, and recording methods compared with
conventional ECG (291).
AECG monitoring may be used to identify asymptomatic
patients with congenital complete AV block at increased
risk for sudden arrhythmic events and who thus may benefit
from prophylactic pacemaker implantation (292). Con-
versely, routine AECG evaluation of asymptomatic patients
with preexcitation syndromes (Wolff-Parkinson-White) has
not been demonstrated to define patients at risk for sudden
arrhythmic death (293).
Unexplained syncope or cardiovascular collapse in pa-
tients with cardiovascular disease generally requires in-
hospital continuous ECG monitoring, with an invasive
evaluation when the cause of the event is uncertain (294).
However, if a cause cannot be established by invasive
methods, AECG monitoring may be used for subsequent
evaluation to evaluate for both transient bradyarrhythmias
and tachyarrhythmias (295).
C. Other Medical Conditions
Arrhythmias have become increasingly recognized in
young patients with a number of diverse medical conditions.
These include Duchenne or Becker muscular dystrophy,
myotonic dystrophy, and patients who are survivors of
childhood malignancies. Limited data would suggest that
AECG monitoring may be indicated in these patients in the
presence of symptoms compatible with an arrhythmia be-
cause of the potential for both ventricular arrhythmias and
progressive conduction system disease (296–299).
D. Evaluation After Therapy or Intervention
AECG monitoring is useful to evaluate both beneficial
and potentially adverse responses to pharmacological ther-
apy in pediatric patients (300,301). The limitations of
AECG monitoring as the result of day-to-day variance in
ventricular ectopy have been discussed in Section 6. Addi-
tional indications for AECG monitoring include the eval-
uation of symptoms in patients with pacemakers or after
radiofrequency catheter ablation or heart surgery, particu-
larly when complicated by transient AV block (302,303).
Specific considerations in the use of AECG monitoring for
assessment of pacemaker function are addressed in Section
7. AECG monitoring is also indicated for the evaluation of
cardiac rhythm after treatment of incessant tachyarrhyth-
mias, which have been associated with progressive ventric-
ular dysfunction (304).
Indications for AECG Monitoring in Pediatric
Patients
Class I
1. Syncope, near syncope, or dizziness in patients with
recognized heart disease, previously documented
arrhythmia, or pacemaker dependency
2. Syncope or near syncope associated with exertion
when the cause is not established by other methods
3. Evaluation of patients with hypertrophic or dilated
cardiomyopathies
4. Evaluation of possible or documented long QT
syndromes
5. Palpitation in the patient with prior surgery for
congenital heart disease and significant residual
hemodynamic abnormalities
6. Evaluation of antiarrhythmic drug efficacy during
rapid somatic growth
7. Asymptomatic congenital complete AV block, non-
paced
Class IIa
1. Syncope, near syncope, or sustained palpitation in
the absence of a reasonable explanation and where
there is no overt clinical evidence of heart disease
2. Evaluation of cardiac rhythm after initiation of an
antiarrhythmic therapy, particularly when associ-
ated with a significant proarrhythmic potential
3. Evaluation of cardiac rhythm after transient AV
block associated with heart surgery or catheter
ablation
4. Evaluation of rate-responsive or physiological pac-
ing function in symptomatic patients
Class IIb
1. Evaluation of asymptomatic patients with prior
surgery for congenital heart disease, particularly
when there are either significant or residual hemo-
dynamic abnormalities, or a significant incidence of
late postoperative arrhythmias
2. Evaluation of the young patient (<3 years) with a
prior tachyarrhythmia to determine if unrecognized
episodes of the arrhythmia recur
3. Evaluation of the patient with a suspected incessant
atrial tachycardia
4. Complex ventricular ectopy on ECG or exercise test
Class III
1. Syncope, near syncope, or dizziness when a noncar-
diac cause is present
2. Chest pain without clinical evidence of heart dis-
ease
3. Routine evaluation of asymptomatic individuals for
athletic clearance
4. Brief palpitation in the absence of heart disease
5. Asymptomatic Wolff-Parkinson-White syndrome
938 Crawford et al. JACC Vol. 34, No. 3, 1999
ACC/AHA Guidelines for Ambulatory Electrocardiography September 1999:912–48
STAFF
American College of Cardiology
Christine W. McEntee, Executive Vice President
Mary Anne Elma, Manager, Practice Guidelines
Kimberly Harris, Manager, Practice Guidelines
Gwen C. Pigman, MLS, Assistant Director, On-Line and
Library Services
American Heart Association
Office of Scientific Affairs
Rodman D. Starke, MD, FACC, Senior Vice President for
Science and Medicine
Kathryn A. Taubert, PhD, Senior Scientist
REFERENCES
1. Knoebel SB, Crawford MH, Dunn MI, et al. Guidelines for ambulatory
electrocardiography: a report of the American College of Cardiology/
American Heart Association Task Force on Assessment of Diagnostic
and Therapeutic Cardiovascular Procedures (Subcommittee on Ambu-
latory Electrocardiography). J Am Coll Cardiol 1989;13:249–58.
2. Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA Guide-
lines for the Clinical Application of Echocardiography: a report of the
American College of Cardiology/American Heart Association Task
Force on Practice Guidelines (Committee on Clinical Application of
Echocardiography). Developed in Collaboration with the American
Society of Echocardiography. Circulation 1997;95:1686–744.
3. Association for the Advancement of Medical Instrumentation.
American national standard: ambulatory electrocardiographs. Arling-
ton, VA: ANSI/AAMI; 1994. EC 38.
4. Bragg-Remschel DA, Anderson CM, et al. Frequency response
characteristics of ambulatory ECG monitoring systems and their
implications for ST segment analysis. Am Heart J 1982;103:20–31.
5. Shook TL, Balke CW, Kotilainen PW, et al. Comparison of
amplitude-modulated (direct) and frequency-modulated ambulatory
techniques for recording ischemic electrocardiographic changes. Am J
Cardiol 1987;60:895–900.
6. Nearing BD, Stone PH, Verrier RL. Frequency response character-
istics required for detection of T-wave alternans during ambulatory
ECG monitoring. Ann Noninvas Electrocardiol 1996;1:103–12.
7. Phadke K, Mulcahy D, Fox K. Clinical validation of four solid state
ambulatory monitoring devices in detecting shift of the ST segment.
Int J Cardiol 1991;33:445–6.
8. Lanza GA, Lucente M, Rebuzzi AG, et al. Accuracy in clinical
arrhythmia detection of a real-time Holter system (Oxford Medilog
4500). J Electrocardiol 1990;23:301–6.
9. Kennedy HL, et al. Limitations of ambulatory ECG real-time
analysis for ventricular and supraventricular arrhythmia accuracy
detected by clinical evaluation. Am J Noninvas Cardiol 1992;6:137–46.
10. Lanza GA, Mascellanti M, Placentino M, et al. Usefulness of a third
Holter lead for detection of myocardial ischemia. Am J Cardiol
1994;74:1216–9.
11. Seeberger MD, Moerlen J, Skarvan K, et al. The inverse Nehb J lead
increases the sensitivity of Holter electrocardiographic monitoring for
detecting myocardial ischemia. Am J Cardiol 1997;80:1–5.
12. DiMarco JP, Philbrick JT. Use of ambulatory electrocardiographic
(Holter) monitoring. Ann Intern Med 1990;113:53–68.
13. Pratt CM, Theroux P, Slymen D, et al. Spontaneous variability of
ventricular arrhythmias in patients at increased risk for sudden death
after acute myocardial infarction: consecutive ambulatory electrocar-
diographic recordings of 88 patients. Am J Cardiol 1987;59:278–83.
14. Mulrow JP, Healy MJ, McKenna WJ. Variability of ventricular
arrhythmias in hypertrophic cardiomyopathy and implications for
treatment. Am J Cardiol 1986;58:615–8.
15. Pratt CM, Delclos G, Wierman AM, et al. The changing baseline of
complex ventricular arrhythmias: a new consideration in assessing
long-term antiarrhythmic drug therapy. N Engl J Med 1985;313:
1444–9.
16. Raeder EA, Hohnloser SH, Graboys TB, et al. Spontaneous vari-
ability and circadian distribution of ectopic activity in patients with
malignant ventricular arrhythmia. J Am Coll Cardiol 1988;12:656–61.
17. Toivonen L. Spontaneous variability in the frequency of ventricular
premature complexes over prolonged intervals and implications for
antiarrhythmic treatment. Am J Cardiol 1987;60:608–12.
18. Michelson EL, Morganroth J. Spontaneous variability of complex
ventricular arrhythmias detected by long-term electrocardiographic
recording. Circulation 1980;61:690–5.
19. Pratt CM, Slymen DJ, Wierman AM, et al. Analysis of the
spontaneous variability of ventricular arrhythmias: consecutive am-
bulatory electrocardiographic recordings of ventricular tachycardia.
Am J Cardiol 1985;56:67–72.
20. Morganroth J, Michelson EL, Horowitz LN, et al. Limitations of
routine long-term electrocardiographic monitoring to assess ventric-
ular ectopic frequency. Circulation 1978;58:408–14.
21. Anastasiou-Nana MI, Menlove RL, Nanas JN, et al. Changes in
spontaneous variability of ventricular ectopic activity as a function of
time in patients with chronic arrhythmias. Circulation 1988;78:286–95.
22. Schmidt G, Ulm K, Barthel P, et al. Spontaneous variability of simple
and complex ventricular premature contractions during long time
intervals in patients with severe organic heart disease. Circulation
1988;78:296–301.
23. Bass EB, Curtiss EI, Arena VC, et al. The duration of Holter
monitoring in patients with syncope: is 24 hours enough? Arch Intern
Med 1990;150:1073–8.
24. Deanfield JE, Maseri A, Selwyn AP, et al. Myocardial ischaemia
during daily life in patients with stable angina: its relation to
symptoms and heart rate changes. Lancet 1983;2:753–8.
25. Tzivoni D, Gavish A, Benhorin J, et al. Day-to-day variability of
myocardial ischemic episodes in coronary artery disease. Am J
Cardiol 1987;60:1003–5.
26. Nabel EG, Barry J, Rocco MB, et al. Variability of transient
myocardial ischemia in ambulatory patients with coronary artery
disease. Circulation 1988;78:60–7.
27. Nademanee K, Christenson PD, Intarachot V, et al. Variability of
indexes for myocardial ischemia: a comparison of exercise treadmill
test, ambulatory electrocardiographic monitoring and symptoms of
myocardial ischemia. J Am Coll Cardiol 1989;13:574–9.
28. Celermajer DS, Spiegelhalter DJ, Deanfield M, et al. Variability of
episodic ST segment depression in chronic stable angina: implica-
tions for individual and group trials of therapeutic efficacy. J Am Coll
Cardiol 1994;23:66–73.
29. Andrews TC, Fenton T, Toyosaki N, et al. Subsets of ambulatory
myocardial ischemia based on heart rate activity: circadian distribu-
tion and response to anti-ischemic medication: the Angina and Silent
Ischemia Study Group (ASIS). Circulation 1993;88:92–100.
30. Stone PH, McMahon RP, Andrews TC, et al. Heart rate during
daily activities and reproducibility of ischemia using ambulatory ECG
monitoring: the Psychophysiological Investigations of Myocardial
Ischemia (PIMI) study (abstr). Circulation 1996;94 Suppl I:I-78.
31. Roelke M, Ruskin JM. Arrhythmias detected with implantable
cardioverter-defibrillators. In: Moss AJ, editor. Noninvasive electro-
cardiography: clinical aspects of Holter monitoring. Philadelphia,
PA: WB Saunders Co Ltd, 1996:93–105.
32. Coumel P, Thomas O, Leenhardt A. Holter functions of the
implantable cardioverter defibrillator: what is still missing? Pacing
Clin Electrophysiol 1995;18:560–8.
33. Pratt CM, Eaton T, Francis M, et al. Ambulatory electrocardio-
graphic recordings: the Holter monitor. Curr Probl Cardiol 1988;13:
517–86.
34. Stone PH, Chaitman BR, McMahon RP, et al. The Asymptomatic
Cardiac Ischemia Pilot (ACIP) Study: relationship between exercise-
induced and ambulatory ischemia in patients with stable coronary
disease. Circulation 1996;94:1537–44.
35. Cohn PF, Kannel WB. Recognition, pathogenesis, and management
options in silent coronary artery disease. Circulation 1987;75:II1.
36. Algra A, Tijssen JG, Roelandt JR, et al. QT interval variables from 24
hour electrocardiography and the 2 year risk of sudden death. Br
Heart J 1993;70:43–8.
37. Zareba W. Ventricular repolarization measures: QT interval, Rtm
interval or T wave loop morphology? Ann Noninvas Electrocardiol
1997;2:101–3.
38. Schneider AE, Plewan A, Schmitt C, et al. The signal-averaged
939JACC Vol. 34, No. 3, 1999 Crawford et al.
September 1999:912–48 ACC/AHA Guidelines for Ambulatory Electrocardiography
ECG obtained by a new digital Holter recording system. Ann
Noninvas Electrocardiol 1996;1:379–85.
39. Bigger JT. Spectral analysis of R-R variability to evaluate autonomic
physiology and pharmacology and to predict cardiovascular outcomes
in humans. In: Zipes DP, editor. Cardiac electrophysiology: from cell
to bedside. 2nd ed. Philadelphia, PA: WB Saunders Co, 1995:1151–
70.
40. Malik M, Camm AJ. Components of heart rate variability: what they
really mean and what we really measure. Am J Cardiol 1993;72:
821–2.
41. Stein KS, Bosner MD, Kleiger RE, et al. Heart rate variability: a
measure of cardiac autonomic tone. Am Heart J 1994;127:1376–81.
42. Pagani M, Lombardi F, Malliani A. Heart rate variability: disagree-
ment on the markers of sympathetic and parasympathetic activities.
J Am Coll Cardiol 1993;22:951–3.
43. Akselrod S, Gordon D, Ubel FA, et al. Power spectrum analysis of
heart rate fluctuation: a quantitative probe of beat-to-beat cardiovas-
cular control. Science 1981;213:220–2.
44. Pomeranz B, Macaulay RJ, Caudill MA, et al. Assessment of
autonomic function in humans by heart rate spectral analysis. Am J
Physiol 1985;248:H151–3.
45. Task Force of the European Society of Cardiology and the North
American Society of Pacing and Electrophysiology. Heart rate
variability: standards of measurement, physiological interpretation,
and clinical use. Circulation 1996;93:1043–65.
46. Rinoli T, Porges SW. Inferential and descriptive influences on
measures of respiratory sinus arrhythmia: sampling rate, R-wave
trigger accuracy, and variance estimates. Psychophysiology 1997;34:
613–21.
47. Friesen GM, Jannett TC, Jadallah MA, et al. A comparison of the
noise sensitivity of nine QRS detection algorithms. IEEE Trans
Biomed Eng 1990;37:85–98.
48. Bartoli F, Baselli G, Cerutti S. Application of identification and
linear filtering algorithms to the R-R interval measurements. In:
Computers in cardiology. Silver Spring, Md: IEEE Computer
Society, 1982:485–8.
49. Merri M, Farden DC, Mottley JG, et al. Sampling frequency of the
electrocardiogram for spectral analysis of the heart rate variability.
IEEE Trans Biomed Eng 1990;37:99–106.
50. Cheung MN. Detection of and recovery from errors in cardiac
interbeat intervals. Psychophysiology 1981;18:341–6.
51. Berntson GG, Quigley KS, Jang JF, et al. An approach to artifact
identification: application to heart period data. Psychophysiology
1990;27:586–98.
52. Linden W, Estrin R. Computerized cardiovascular monitoring:
method and data. Psychophysiology 1988;25:227–34.
53. Saul JP, Arai Y, Berger RD, et al. Assessment of autonomic
regulation in chronic congestive heart failure by heart rate spectral
analysis. Am J Cardiol 1988;61:1292–9.
54. Kleiger RE, Bigger JT, Bosner MS, et al. Stability over time of
variables measuring heart rate variability in normal subjects. Am J
Cardiol 1991;68:626–30.
55. Umetani K, Singer D, McCraty R, et al. Twenty-four hour time
domain heart rate variability and heart rate: relations to age and
gender over 9 decades. J Am Coll Cardiol 1998;31:593–601.
56. Bigger JT, Fleiss JL, Steinman RC, et al. Correlations among time
and frequency domain measures of heart period variability 2 weeks
after acute myocardial infarction. Am J Cardiol 1992;69:891–8.
57. Stein PK, Rottman JN, Kleiger RE. Time domain measure of heart
rate variability as surrogates for frequency domain measures in stable
congestive heart failure patients and normals (abstr). Circulation
1994;90 Suppl I:I–331.
58. Diamond TH, Smith R, Myburgh DP. Holter monitoring: a
necessity for the evaluation of palpitations. S Afr Med J 1983;63:5–7.
59. Kapoor WN, Cha R, Peterson JR, et al. Prolonged electrocardio-
graphic monitoring in patients with syncope: importance of frequent
or repetitive ventricular ectopy. Am J Med 1987;82:20–8.
60. Kennedy HL, Underhill SJ. Frequent or complex ventricular ectopy
in apparently healthy subjects: a clinical study of 25 cases. Am J
Cardiol 1976;38:141–8.
61. Raftery EB, Cashman PM. Long-term recording of the electrocar-
diogram in a normal population. Postgrad Med J 1976;52 Suppl
7:32–8.
62. Glasser SP, Clark PI, Applebaum HJ. Occurrence of frequent
complex arrhythmias detected by ambulatory monitoring: findings in
an apparently healthy asymptomatic elderly population. Chest 1979;
75:565–8.
63. Kostis JB, McCrone K, Moreyra AE, et al. Premature ventricular
complexes in the absence of identifiable heart disease. Circulation
1981;63:1351–6.
64. Linzer M, Yang EH, Estes NA, et al. Diagnosing syncope, I: value
of history, physical examination, and electrocardiography: Clinical
Efficacy Assessment Project of the American College of Physicians.
Ann Intern Med 1997;126:989–96.
65. Linzer M, Yang EH, Estes NA, et al. Diagnosing syncope, II:
unexplained syncope: Clinical Efficacy Assessment Project of the
American College of Physicians. Ann Intern Med 1997;127:76–86.
66. Gibson TC, Heitzman MR. Diagnostic efficacy of 24-hour electro-
cardiographic monitoring for syncope. Am J Cardiol 1984;53:
1013–7.
67. Kala R, Viitasalo MT, Toivonen L, et al. Ambulatory ECG record-
ing in patients referred because of syncope or dizziness. Acta Med
Scand Suppl 1982;668:13–9.
68. Zeldis SM, Levine BJ, Michelson EL, et al. Cardiovascular com-
plaints: correlation with cardiac arrhythmias on 24-hour electrocar-
diographic monitoring. Chest 1980;78:456–61.
69. Clark PI, Glasser SP, Spoto E Jr. Arrhythmias detected by ambula-
tory monitoring: lack of correlation with symptoms of dizziness and
syncope. Chest 1980;77:722–5.
70. Bhandari AK, Anderson JL, Gilbert EM, et al. Correlation of
symptoms with occurrence of paroxysmal supraventricular tachycar-
dia or atrial fibrillation: a transtelephonic monitoring study: the
Flecainide Supraventricular Tachycardia Study Group. Am Heart J
1992;124:381–6.
71. Kinlay S, Leitch JW, Neil A, et al. Cardiac event recorders yield more
diagnoses and are more cost-effective than 48-hour Holter monitor-
ing in patients with palpitations: a controlled clinical trial. Ann Intern
Med 1996;124:16–20.
72. Schmidt SB, Jain AC. Diagnostic utility of memory equipped
transtelephonic monitors. Am J Med Sci 1988;296:299–302.
73. Linzer M, Pritchett EL, Pontinen M, et al. Incremental diagnostic
yield of loop electrocardiographic recorders in unexplained syncope.
Am J Cardiol 1990;66:214–9.
74. Shimada M, Akaishi M, Asakura K, et al. Usefulness of the newly
developed transtelephonic electrocardiogram and computer-
supported response system. J Cardiol 1996;27:211–7.
75. Kus T, Nadeau R, Costi P, et al. Comparison of the diagnostic yield
of Holter versus transtelephonic monitoring. Can J Cardiol 1995;11:
891–4.
76. Murdock CJ, Klein GJ, Yee R, et al. Feasibility of long-term
electrocardiographic monitoring with an implanted device for syn-
cope diagnosis. Pacing Clin Electrophysiol 1990;13:1374–8.
77. Leitch J, Klein G, Yee R, et al. Feasibility of an implantable
arrhythmia monitor. Pacing Clin Electrophysiol 1992;15:2232–5.
78. Boudoulas H, Schaal SF, Lewis RP, et al. Superiority of 24-hour
outpatient monitoring over multi-stage exercise testing for the
evaluation of syncope. J Electrocardiol 1979;12:103–8.
79. Jonas S, Klein I, Dimant J. Importance of Holter monitoring in
patients with periodic cerebral symptoms. Ann Neurol 1977;1:
470–4.
80. Page RL, Wilkinson WE, Clair WK, et al. Asymptomatic arrhyth-
mias in patients with symptomatic paroxysmal atrial fibrillation and
paroxysmal supraventricular tachycardia. Circulation 1994;89:224–7.
81. Clair WK, Wilkinson WE, McCarthy EA, et al. Spontaneous
occurrence of symptomatic paroxysmal atrial fibrillation and parox-
ysmal supraventricular tachycardia in untreated patients. Circulation
1993;87:1114–22.
82. Kessler DK, Kessler KM. Is ambulatory electrocardiography useful in
the evaluation of patients with recent stroke? Chest 1995;107:916–8.
83. Assayag P, Chailley O, Lehner JP, et al. Contribution of sequential
voluntary ambulatory monitoring in the diagnosis of arrhythmia: a
multicenter study of 1287 symptomatic patients. Arch Mal Coeur
Vaiss 1992;85:281–6.
84. Bigger JT Jr, Fleiss JL, Kleiger R, et al. The relationships among
ventricular arrhythmias, left ventricular dysfunction, and mortality in
the 2 years after myocardial infarction. Circulation 1984;69:250–8.
85. Multicenter Post-infarction Research Group. Risk stratification and
survival after myocardial infarction. N Engl J Med 1983;309:331–6.
940 Crawford et al. JACC Vol. 34, No. 3, 1999
ACC/AHA Guidelines for Ambulatory Electrocardiography September 1999:912–48
86. McClements BM, Adgey AA. Value of signal-averaged electrocar-
diography, radionuclide ventriculography, Holter monitoring and
clinical variables for prediction of arrhythmic events in survivors of
acute myocardial infarction in the thrombolytic era. J Am Coll
Cardiol 1993;21:1419–27.
87. Hohnloser SH, Franck P, Klingenheben T, et al. Open infarct artery,
late potentials, and other prognostic factors in patients after acute
myocardial infarction in the thrombolytic era: a prospective trial.
Circulation 1994;90:1747–56.
88. Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial of
outcome after myocardial infarction in patients with frequent or
repetitive ventricular premature depolarisations: CAMIAT, Cana-
dian Amiodarone Myocardial Infarction Arrhythmia Trial Investiga-
tors. Lancet 1997;349:675–82.
89. Farrell TG, Bashir Y, Cripps T, et al. Risk stratification for
arrhythmic events in postinfarction patients based on heart rate
variability, ambulatory electrocardiographic variables and the signal-
averaged electrocardiogram. J Am Coll Cardiol 1991;18:687–97.
90. El-Sherif N, Denes P, Katz R, et al. Definition of the best prediction
criteria of the time domain signal-averaged electrocardiogram for
serious arrhythmic events in the postinfarction period: the Cardiac
Arrhythmia Suppression Trial/Signal-Averaged Electrocardiogram
(CAST/SAECG) Substudy Investigators. J Am Coll Cardiol 1995;
25:908–14.
91. Gomes JA, Winters SL, Martinson M, et al. The prognostic
significance of quantitative signal-averaged variables relative to clin-
ical variables, site of myocardial infarction, ejection fraction and
ventricular premature beats: a prospective study. J Am Coll Cardiol
1989;13:377–84.
92. Davis BR, Friedman LM, Lichstein E. The prognostic value of the
duration of the ambulatory electrocardiogram after myocardial infarc-
tion. Med Decis Making 1988;8:9–18.
93. Davis BR, Friedman LM, Lichstein E. Are 24 hours of ambulatory
ECG monitoring necessary for a patient after infarction? Am Heart J
1988;115:83–91.
94. Mukharji J, Rude RE, Poole WK, et al. Risk factors for sudden death
after acute myocardial infarction: 2-year follow-up. Am J Cardiol
1984;54:31–6.
95. Kleiger RE, Miller JP, Bigger JT, et al. Decreased heart rate
variability and its association with increased mortality after acute
myocardial infarction. Am J Cardiol 1987;59:256–62.
96. Kostis JB, Byington R, Friedman LM, et al. Prognostic significance
of ventricular ectopic activity in survivors of acute myocardial infarc-
tion. J Am Coll Cardiol 1987;10:231–42.
97. Kuchar DL, Thorburn CW, Sammel NL. Prediction of serious
arrhythmic events after myocardial infarction: signal-averaged elec-
trocardiogram, Holter monitoring and radionuclide ventriculography.
J Am Coll Cardiol 1987;9:531–8.
98. de Cock CC, Visser FC, van Eenige MJ, et al. Independent
prognostic value of supraventricular arrhythmias on 24-h ambulatory
monitoring following myocardial infarction. Eur Heart J 1991;12:
1070–5.
99. Wilson AC, Kostis JB. The prognostic significance of very low
frequency ventricular ectopic activity in survivors of acute myocardial
infarction: BHAT Study Group. Chest 1992;102:732–6.
100. Pedretti R, Etro MD, Laporta A, et al. Prediction of late arrhythmic
events after acute myocardial infarction from combined use of
noninvasive prognostic variables and inducibility of sustained mono-
morphic ventricular tachycardia. Am J Cardiol 1993;71:1131–41.
101. Denes P, Gillis AM, Pawitan Y, et al. Prevalence, characteristics and
significance of ventricular premature complexes and ventricular
tachycardia detected by 24-hour continuous electrocardiographic
recording in the Cardiac Arrhythmia Suppression Trial. CAST
Investigators. Am J Cardiol 1991;68:887–96.
102. Dittrich H, Gilpin E, Nicod P, et al. Acute myocardial infarction in
women: influence of gender on mortality and prognostic variables.
Am J Cardiol 1988;62:1–7.
103. Moss AJ, Carleen E, the Multicenter Postinfarction Research Group.
Gender differences in the mortality risk associated with ventricular
arrhythmias after myocardial infarction. In: Eaker E, Packard B,
Wenger NK, et al, editors. Coronary heart disease in women. New
York: Haymarket Doyma, Inc, 1986:204–7.
104. Bigger JT, Fleiss JL, Steinman RC, et al. Frequency domain
measures of heart period variability and mortality after myocardial
infarction. Circulation 1992;85:164–71.
105. Zhang YZ, Wang SW, Hu DY, et al. Prediction of life-threatening
arrhythmia in patients after myocardial infarction by late potentials,
ejection fraction and Holter monitoring. Jpn Heart J 1992;33:15–23.
106. La Rovere MT, Bigger JT Jr, Marcus FI, et al. Baroreflex sensitivity
and heart rate variability in prediction of total cardiac mortality after
myocardial infarction: ATRAMI (Autonomic Tone and Reflexes
After Myocardial Infarction) Investigators. Lancet 1998;351:478–
84.
107. Odemuyiwa O, Malik M, Farrell T, et al. Comparison of the
predictive characteristics of heart rate variability index and left
ventricular ejection fraction for all-cause mortality, arrhythmic events
and sudden death after acute myocardial infarction. Am J Cardiol
1991;68:434–9.
108. Bigger JT, Fleiss JL, Rolnitzky LM, et al. Frequency domain
measures of heart period variability to assess risk late after myocardial
infarction. J Am Coll Cardiol 1993;21:729–36.
109. Faber TS, Staunton A, Hnatkova K, et al. Stepwise strategy of using
short- and long-term heart rate variability for risk stratification after
myocardial infarction. Pacing Clin Electrophysiol 1996;19:1845–51.
110. Fei L, Malik M. Short-term and long-term assessment of heart rate
variability for postinfarction risk stratification. In: Malik M, Camm
AJ, editors. Heart rate variability. Armonk, NY: Futura Publishing
Co, Inc; 1995:341–6.
111. Malik M, Camm AJ. Significance of long term components of heart
rate variability for the further prognosis after acute myocardial
infarction. Cardiovasc Res 1990;24:793–803.
112. Bigger JT, Fleiss JL, Rolnitzky LM, et al. The ability of several
short-term measures of RR variability to predict mortality after
myocardial infarction. Circulation 1993;88:927–34.
113. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an
implanted defibrillator in patients with coronary disease at high risk
for ventricular arrhythmia: Multicenter Automatic Defibrillator Im-
plantation Trial Investigators. N Engl J Med 1996;335:1933–40.
114. Sim I, McDonald KM, Lavori PW, et al. Quantitative overview of
randomized trials of amiodarone to prevent sudden cardiac death.
Circulation 1997;96:2823–9.
115. Huang SK, Messer JV, Denes P. Significance of ventricular tachy-
cardia in idiopathic dilated cardiomyopathy: observations in 35
patients. Am J Cardiol 1983;51:507–12.
116. Kron J, Hart M, Schual-Berke S, et al. Idiopathic dilated cardiomy-
opathy: role of programmed electrical stimulation and Holter mon-
itoring in predicting those at risk of sudden death. Chest 1988;93:
85–90.
117. Holmes J, Kubo SH, Cody RJ, et al. Arrhythmias in ischemic and
nonischemic dilated cardiomyopathy: prediction of mortality by
ambulatory electrocardiography. Am J Cardiol 1985;55:146–51.
118. Unverferth DV, Magorien RD, Moeschberger ML, et al. Factors
influencing the 1-year mortality of dilated cardiomyopathy. Am J
Cardiol 1984;54:147–52.
119. Pelliccia F, Gallo P, Cianfrocca C, et al. Relation of complex
ventricular arrhythmias to presenting features and prognosis in
dilated cardiomyopathy. Int J Cardiol 1990;29:47–54.
120. Ikegawa T, Chino M, Hasegawa H, et al. Prognostic significance of
24-hour ambulatory electrocardiographic monitoring in patients with
dilative cardiomyopathy: a prospective study. Clin Cardiol 1987;10:
78–82.
121. Szabo BM, van Veldhuisen DJ, Crijns HJ, et al. Value of ambulatory
electrocardiographic monitoring to identify risk of sudden death in
patients with left ventricular dysfunction and heart failure. Eur
Heart J 1994;15:928–33.
122. Doval HC, Nul DR, Grancelli HO, et al. Nonsustained ventricular
tachycardia in severe heart failure: independent marker of increased
mortality due to sudden death: GESICA-GEMA Investigators.
Circulation 1996;94:3198–203.
123. Kienzle MG, Ferguson DW, Birkett CL, et al. Clinical hemody-
namic and sympathetic neural correlates of heart rate variability in
congestive heart failure. Am J Cardiol 1992;69:761–7.
124. Casolo G, Balli E, Taddei T, et al. Decreased spontaneous heart rate
variability in congestive heart failure. Am J Cardiol 1989;64:1162–7.
125. Townend JN, West JN, Davies MK, et al. Effect of quinapril on
blood pressure and heart rate in congestive heart failure. Am J Cardiol
1992;69:1587–90.
941JACC Vol. 34, No. 3, 1999 Crawford et al.
September 1999:912–48 ACC/AHA Guidelines for Ambulatory Electrocardiography
126. Binkley PF, Haas GJ, Starling RC, et al. Sustained augmentation of
parasympathetic tone with angiotensin-converting enzyme inhibition
in patients with congestive heart failure. J Am Coll Cardiol 1993;21:
655–61.
127. Hoffmann J, Grimm W, Menz V, et al. Heart rate variability and
major arrhythmic events in patients with idiopathic dilated cardio-
myopathy. Pacing Clin Electrophysiol 1996;19:1841–4.
128. Hohnloser SH, Klingenheben T, van de Loo A, et al. Reflex versus
tonic vagal activity as a prognostic parameter in patients with
sustained ventricular tachycardia or ventricular fibrillation. Circula-
tion 1994;89:1068–73.
129. Fei L, Keeling PJ, Gill JS, et al. Heart rate variability and its relation
to ventricular arrhythmias in congestive heart failure. Br Heart J
1994;71:322–8.
130. Ponikowski P, Anker SD, Chua TP, et al. Depressed heart rate
variability as an independent predictor of death in chronic congestive
heart failure secondary to ischemic or idiopathic dilated cardiomyop-
athy. Am J Cardiol 1997;79:1645–50.
131. Fauchier L, Babuty D, Cosnay P, et al. Heart rate variability in
idiopathic dilated cardiomyopathy: characteristics and prognostic
value. J Am Coll Cardiol 1997;30:1009–14.
132. Jiang W, Hathaway WR, McNulty S, et al. Ability of heart rate
variability to predict prognosis in patients with advanced congestive
heart failure. Am J Cardiol 1997;80:808–11.
133. Maron BJ, Savage DD, Wolfson JK, et al. Prognostic significance of
24 hour ambulatory electrocardiographic monitoring in patients with
hypertrophic cardiomyopathy: a prospective study. Am J Cardiol
1981;48:252–7.
134. Fananapazir L, Chang AC, Epstein SE, et al. Prognostic determi-
nants in hypertrophic cardiomyopathy. Circulation 1992;86:730–40.
135. McKenna WJ, Oakley CM, Krikler DM, et al. Improved survival
with amiodarone in patients with hypertrophic cardiomyopathy and
ventricular tachycardia. Br Heart J 1985;53:412–6.
136. Counihan PJ, Fei L, Bashir Y, et al. Assessment of heart rate
variability in hypertrophic cardiomyopathy: association with clinical
and prognostic features. Circulation 1993;88:1682–90.
137. Marangoni S, Scalvini S, Mai R, et al. Heart rate variability
assessment in patients with mitral valve prolapse syndrome. Am J
Noninvas Cardiol 1993;7:210–4.
138. Stein KM, Borer JS, Hochreiter C, et al. Prognostic value and
physiological correlates of heart rate variability in chronic severe
mitral regurgitation. Circulation 1993;88:127–35.
139. Hoffmann A, Burckhardt D. Patients at risk for cardiac death late
after aortic valve replacement. Am Heart J 1990;120:1142–7.
140. Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic
autonomic neuropathy. Q J Med 1980;49:95–108.
141. Malpas SC, Maling TJ. Heart-rate variability and cardiac autonomic
function in diabetes. Diabetes 1990;39:1177–81.
142. Ewing DJ, Neilson JM, Shapiro CM, et al. Twenty four hour heart
rate variability: effects of posture, sleep, and time of day in healthy
controls and comparison with bedside tests of autonomic function in
diabetic patients. Br Heart J 1991;65:239–44.
143. Pagani M, Malfatto G, Pierini S, et al. Spectral analysis of heart rate
variability in the assessment of autonomic diabetic neuropathy.
J Auton Nerv Syst 1988;23:143–53.
144. Bellavere F, Balzani I, De Masi G, et al. Power spectral analysis of
heart-rate variations improves assessment of diabetic cardiac auto-
nomic neuropathy. Diabetes 1992;41:633–40.
145. Blumberg A, Hausermann M, Strub B, et al. Cardiac arrhythmias in
patients on maintenance hemodialysis. Nephron 1983;33:91–5.
146. Abe S, Yoshizawa M, Nakanishi N, et al. Electrocardiographic
abnormalities in patients receiving hemodialysis. Am Heart J 1996;
131:1137–44.
147. D’Elia JA, Weinrauch LA, Gleason RE, et al. Application of the
ambulatory 24-hour electrocardiogram in the prediction of cardiac
death in dialysis patients. Arch Intern Med 1988;148:2381–5.
148. Lown B, Wolfe M. Approaches to sudden death from coronary artery
disease. Circulation 1971;44:130–42.
149. Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by
electrocardiogram: prevalence, incidence, and mortality in the Fra-
mingham study. Ann Intern Med 1969;71:89–105.
150. Messerli FH, Ventura HO, Elizardi DJ, et al. Hypertension and
sudden death: increased ventricular ectopic activity in left ventricular
hypertrophy. Am J Med 1984;77:18–22.
151. McLenachan JM, Henderson E, Morris KI, et al. Ventricular
arrhythmias in patients with hypertensive left ventricular hypertro-
phy. N Engl J Med 1987;317:787–92.
152. Siegel D, Cheitlin MD, Black DM, et al. Risk of ventricular
arrhythmias in hypertensive men with left ventricular hypertrophy.
Am J Cardiol 1990;65:742–7.
153. Ferrara N, Furgi G, Longobardi G, et al. Relation between age, left
ventricular mass and ventricular arrhythmias in patients with hyper-
tension. J Hum Hypertens 1995;9:581–7.
154. Kannel WB, Dannenberg AL, Levy D. Population implications of
electrocardiographic left ventricular hypertrophy. Am J Cardiol 1987;
60:85I–93I.
155. Levy D, Anderson KM, Savage DD, et al. Risk of ventricular
arrhythmias in left ventricular hypertrophy: the Framingham Heart
Study. Am J Cardiol 1987;60:560–5.
156. Bikkina M, Larson MG, Levy D. Asymptomatic ventricular arrhyth-
mias and mortality risk in subjects with left ventricular hypertrophy.
J Am Coll Cardiol 1993;22:1111–6.
157. O’Kelly B, Browner WS, Massie B, et al. Ventricular arrhythmias in
patients undergoing noncardiac surgery: the Study of Perioperative
Ischemia Research Group. JAMA 1992;268:217–21.
158. Huikuri HV, Yli-Mayry S, Korhonen UR, et al. Prevalence and
prognostic significance of complex ventricular arrhythmias after
coronary arterial bypass graft surgery. Int J Cardiol 1990;27:333–9.
159. Juul-Moller S, Hedblad B, Janzon L, et al. Increased occurrence of
arrhythmias in men with ischaemic type ST-segment depression
during long-term ECG recording: prognostic impact on ischaemic
heart disease: results from the prospective population study ‘Men
born in 1914,’ Malmo, Sweden. J Intern Med 1991;230:143–9.
160. Gheno G, Mazzei G. Prognostic value of Holter monitoring in
asymptomatic elderly subjects with sinus rhythm. J Electrocardiol
1996;29:39–44.
161. Martin A, Benbow LJ, Butrous GS, et al. Five-year follow-up of 101
elderly subjects by means of long-term ambulatory cardiac monitor-
ing. Eur Heart J 1984;5:592–6.
162. Kennedy HL, Whitlock JA, Sprague MK, et al. Long-term
follow-up of asymptomatic healthy subjects with frequent and com-
plex ventricular ectopy. N Engl J Med 1985;312:193–7.
163. Bikkina M, Larson MG, Levy D. Prognostic implications of asymp-
tomatic ventricular arrhythmias: the Framingham Heart Study. Ann
Intern Med 1992;117:990–6.
164. Shih HT, Webb CR, Conway WA, et al. Frequency and significance
of cardiac arrhythmias in chronic obstructive lung disease. Chest
1988;94:44–8.
165. Fabian TC, Cicala RS, Croce MA, et al. A prospective evaluation of
myocardial contusion: correlation of significant arrhythmias and
cardiac output with CPK-MB measurements. J Trauma 1991;31:
653–60.
166. Zohar Y, Talmi YP, Frenkel H, et al. Cardiac function in obstructive
sleep apnea patients following uvulopalatopharyngoplasty. Otolaryn-
gol Head Neck Surg 1992;107:390–4.
167. Flemons WW, Remmers JE, Gillis AM. Sleep apnea and cardiac
arrhythmias. Is there a relationship? Am Rev Respir Dis 1993;148:
618–21.
168. Snisarenko AA. Cardiac rhythm in cats during physiological sleep in
experimental myocardial infarction and beta-adrenergic receptor
blockade. Cor Vasa 1986;28:306–14.
169. Molgaard H, Mickley H, Pless P, et al. Effects of metoprolol on heart
rate variability in survivors of acute myocardial infarction. Am J
Cardiol 1993;71:1357–9.
170. Filipecki A, Trusz-Gluza M, Szydlo K, et al. Effect of propranolol
and propafenone on heart rate variability in patients with ventricular
arrhythmias (abstr). Pacing Clin Electrophysiol 1993;16:1157.
171. Bekheit S, Tangella M, el-Sakr A, et al. Use of heart rate spectral
analysis to study the effects of calcium channel blockers on sympa-
thetic activity after myocardial infarction. Am Heart J 1990;119:79–
85.
172. Zuanetti G, Latini R, Neilson JM, et al. Heart rate variability in
patients with ventricular arrhythmias: effect of antiarrhythmic drugs:
Antiarrhythmic Drug Evaluation Group (ADEG). J Am Coll Car-
diol 1991;17:604–12.
173. Hohnloser SH, Klingenheben T, Zabel M, et al. Effect of sotalol on
heart rate variability assessed by Holter monitoring in patients with
ventricular arrhythmias: effect of sotalol on heart rate variability
942 Crawford et al. JACC Vol. 34, No. 3, 1999
ACC/AHA Guidelines for Ambulatory Electrocardiography September 1999:912–48
assessed by Holter monitoring in patients with ventricular arrhyth-
mias. Am J Cardiol 1993;72:67A–71A.
174. Olson HG, Lyons KP, Troop P, et al. The high-risk acute myocar-
dial infarction patient at 1-year follow-up: identification at hospital
discharge by ambulatory electrocardiography and radionuclide ven-
triculography. Am Heart J 1984;107:358–66.
175. Richards DA, Byth K, Ross DL, et al. What is the best predictor of
spontaneous ventricular tachycardia and sudden death after myocar-
dial infarction? Circulation 1991;83:756–63.
176. Olona M, Candell-Riera J, Permanyer-Miralda G, et al. Strategies
for prognostic assessment of uncomplicated first myocardial infarc-
tion: 5-year follow-up study. J Am Coll Cardiol 1995;25:815–22.
177. Anderson JL, Gilbert EM, Alpert BL, et al. Prevention of symp-
tomatic recurrences of paroxysmal atrial fibrillation in patients ini-
tially tolerating antiarrhythmic therapy: a multicenter, double-blind,
crossover study of flecainide and placebo with transtelephonic mon-
itoring: Flecainide Supraventricular Tachycardia Study Group. Cir-
culation 1989;80:1557–70.
178. Winkle RA, Peters F, Hall R. Characterization of ventricular
tachyarrhythmias on ambulatory ECG recordings in post-myocardial
infarction patients: arrhythmia detection and duration of recording,
relationship between arrhythmia frequency and complexity, and
day-to-day reproducibility. Am Heart J 1981;102:162–9.
179. The Cardiac Arrhythmia Pilot Study (CAPS) Investigators. Effects
of encainide, flecainide, imipramine and moricizine on ventricular
arrhythmias during the year after acute myocardial infarction: the
CAPS. Am J Cardiol 1988;61:501–9.
180. Reiter MJ, Karagounis LA, Mann DE, et al. Reproducibility of drug
efficacy predictions by Holter monitoring in the electrophysiologic
study versus electrocardiographic monitoring (ESVEM) trial:
ESVEM Investigators. Am J Cardiol 1997;79:315–22.
181. Anastasiou-Nana MI, Gilbert EM, Miller RH, et al. Usefulness of
d,l sotalol for suppression of chronic ventricular arrhythmias. Am J
Cardiol 1991;67:511–6.
182. Kennedy HL. Noncardiac adverse events and organ toxicity of
moricizine during short- and long-term studies. Am J Cardiol
1990;65:47D–50D.
183. Schmidt G, Ulm K, Barthel P. Variability of ventricular premature
contractions (letter). Circulation 1989;79:1149–51.
184. Anderson JL, Anastasiou-Nana MI, Menlove RL, et al. Spontaneous
variability in ventricular ectopic activity during chronic antiarrhyth-
mic therapy. Circulation 1990;82:830–40.
185. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators.
Preliminary report: effect of encainide and flecainide on mortality in
a randomized trial of arrhythmia suppression after myocardial infarc-
tion. N Engl J Med 1989;321:406–12.
186. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in
patients receiving encainide, flecainide, or placebo: the Cardiac
Arrhythmia Suppression Trial. N Engl J Med 1991;324:781–8.
187. Effect of the antiarrhythmic agent moricizine on survival after
myocardial infarction: the Cardiac Arrhythmia Suppression Trial II
Investigators. N Engl J Med 1992;327:227–33.
188. Epstein AE, Hallstrom AP, Rogers WJ, et al. Mortality following
ventricular arrhythmia suppression by encainide, flecainide, and
moricizine after myocardial infarction: the original design concept of
the Cardiac Arrhythmia Suppression Trial (CAST). JAMA 1993;
270:2451–5.
189. Wyse DG, Hallstrom A, McBride R, et al. Events in the Cardiac
Arrhythmia Suppression Trial (CAST): mortality in patients surviv-
ing open label titration but not randomized to double-blind therapy.
J Am Coll Cardiol 1991;18:20–8.
190. Hallstrom AP, Greene HL, Huther ML. The healthy responder
phenomenon in non-randomized clinical trials. CAST Investigators.
Stat Med 1991;10:1621–31.
191. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhyth-
mic drug therapy in acute myocardial infarction: an overview of
results from randomized controlled trials. JAMA 1993;270:1589–95.
192. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on
mortality in patients with left ventricular dysfunction after recent and
remote myocardial infarction: the SWORD Investigators: Survival
With Oral d-Sotalol. Lancet 1996;348:7–12.
193. Burkart F, Pfisterer M, Kiowski W, et al. Effect of antiarrhythmic
therapy on mortality in survivors of myocardial infarction with
asymptomatic complex ventricular arrhythmias: Basel Antiarrhyth-
mic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990;16:
1711–8.
194. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, et al. Effect of
amiodarone on mortality after myocardial infarction: a double-blind,
placebo-controlled, pilot study. J Am Coll Cardiol 1992;20:1056–62.
195. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of
low-dose amiodarone in severe congestive heart failure: Grupo de
Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina
(GESICA). Lancet 1994;344:493–8.
196. The CASCADE Investigators. Randomized drug therapy in survi-
vors of cardiac arrest (the CASCADE Study). Am J Cardiol
1993;72:280–7.
197. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of
amiodarone on mortality in patients with left-ventricular dysfunction
after recent myocardial infarction: EMIAT, European Myocardial
Infarct Amiodarone Trial Investigators. Lancet 1997;349:667–74.
198. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients
with congestive heart failure and asymptomatic ventricular arrhyth-
mia: Survival Trial of Antiarrhythmic Therapy in Congestive Heart
Failure. N Engl J Med 1995;333:77–82.
199. Graboys TB, Lown B, Podrid PJ, et al. Long-term survival of
patients with malignant ventricular arrhythmia treated with antiar-
rhythmic drugs. Am J Cardiol 1982;50:437–43.
200. Lampert S, Lown B, Graboys TB, et al. Determinants of survival in
patients with malignant ventricular arrhythmia associated with cor-
onary artery disease. Am J Cardiol 1988;61:791–7.
201. Mitchell LB, Duff HJ, Manyari DE, et al. A randomized clinical trial
of the noninvasive and invasive approaches to drug therapy of
ventricular tachycardia. N Engl J Med 1987;317:1681–7.
202. Mason JW. A comparison of electrophysiologic testing with Holter
monitoring to predict antiarrhythmic-drug efficacy for ventricular
tachyarrhythmias: Electrophysiologic Study Versus Electrocardio-
graphic Monitoring Investigators. N Engl J Med 1993;329:445–51.
203. The Antiarrhythmics Versus Implantable Defibrillators (AVID)
Investigators. A comparison of antiarrhythmic-drug therapy with
implantable defibrillators in patients resuscitated from near-fatal
ventricular arrhythmias. N Engl J Med 1997;337:1576–83.
204. Swerdlow CD, Peterson J. Prospective comparison of Holter moni-
toring and electrophysiologic study in patients with coronary artery
disease and sustained ventricular tachyarrhythmias. Am J Cardiol
1985;56:577–80.
205. Pritchett EL, Lee KL. Designing clinical trials for paroxysmal atrial
tachycardia and other paroxysmal arrhythmias. J Clin Epidemiol
1988;41:851–8.
206. Jung F, DiMarco JP. Antiarrhythmic drug therapy in the treatment
of atrial fibrillation. Cardiol Clin 1996;14:507–20.
207. Kennedy HL. Late proarrhythmia and understanding the time of
occurrence of proarrhythmia. Am J Cardiol 1990;66:1139–43.
208. Morganroth J, Pratt CM. Prevalence and characteristics of proar-
rhythmia from moricizine (Ethmozine). Am J Cardiol 1989;63:
172–6.
209. Wyse DG, Morganroth J, Ledingham R, et al. New insights into the
definition and meaning of proarrhythmia during initiation of antiar-
rhythmic drug therapy from the Cardiac Arrhythmia Suppression
Trial and its pilot study: the CAST and CAPS Investigators. J Am
Coll Cardiol 1994;23:1130–40.
210. Furman S, Hayes DL, Homes DR. Telemetry. In: A practice of
cardiac pacing. 3rd ed. Mt Kisco, NY: Futura Publishing; 1993:633.
211. Newman D, Dorian P, Downar E, et al. Use of telemetry function in
the assessment of implanted antitachycardia device efficacy. Am J
Cardiol 1992;70:616–21.
212. Lascault G, Frank R, Himbert C, et al. Diagnosis of ventricular
tachycardia using a pacemaker Holter function. Pacing Clin Electro-
physiol 1994;17:1316–9.
213. Levine PA, Sanders R, Rankowitz HT. Pacemaker diagnostics:
measured data, event marker, electrogram, and event counter telem-
etry. In: Ellenbogen KA, Kay GN, Wilkoll BL, editors. Clinical
cardiac pacing. Philadelphia, PA: WB Saunders Co; 1995:639–55.
214. Ben-Zur U, Platt SB, Gross JN, et al. Direct and telemetered lead
impedance. Pacing Clin Electrophysiol 1994;17:2004–7.
215. Schuchert A, Cappato R, Kuck KH, et al. Reliability and variability
of impedance measured by real-time telemetry. Pacing Clin Electro-
physiol 1996;19:265–71.
216. Dreifus LS, Fisch C, Griffin JC, et al. Guidelines for implantation of
943JACC Vol. 34, No. 3, 1999 Crawford et al.
September 1999:912–48 ACC/AHA Guidelines for Ambulatory Electrocardiography
cardiac pacemakers and antiarrhythmia devices: a report of the
American College of Cardiology/American Heart Association Task
Force on Assessment of Diagnostic and Therapeutic Cardiovascular
Procedures (Committee on Pacemaker Implantation). J Am Coll
Cardiol 1991;18:1–13.
217. Janosik DL, Redd RM, Buckingham TA, et al. Utility of ambulatory
electrocardiography in detecting pacemaker dysfunction in the early
postimplantation period. Am J Cardiol 1987;60:1030–5.
218. Begemann MJ, Boute W. Heart rate monitoring in implanted
pacemakers. Pacing Clin Electrophysiol 1988;11:1687–92.
219. Nowak B, Middeldorf T, Housworth CM, et al. Holter recordings
with continuous marker annotations: a new tool in pacemaker
diagnostics. Pacing Clin Electrophysiol 1996;19:1791–5.
220. Reiter MJ, Fain ES, Senelly KM, et al. Predictors of device activation
for ventricular arrhythmias and survival in patients with implantable
pacemakers/defibrillators: CADENCE Investigators. Pacing Clin
Electrophysiol 1994;17:1487–98.
221. Birgersdotter-Green U, Rosenqvist M, Lindemans FW, et al. Holter
documented sudden death in a patient with an implanted defibrilla-
tor. Pacing Clin Electrophysiol 1992;15:1008–14.
222. Callans DJ, Hook BG, Kleiman RB, et al. Unique sensing errors in
third-generation implantable cardioverter-defibrillators. J Am Coll
Cardiol 1993;22:1135–40.
223. Krahn AD, Klein GJ, Yee R, et al. Use of an extended monitoring
strategy in patients with problematic syncope. Circulation 1999;99:
406–10.
224. Mugica J, Thornander H. An experimental implantable “Holter.” In:
Feruglio G, editor. Cardiac pacing: electrophysiology and pacemaker
technology. Padova, Italy: Piccin Medical Books; 1991:1311–4.
225. Crawford MH, Mendoza CA, O’Rourke RA, et al. Limitations of
continuous ambulatory electrocardiogram monitoring for detecting
coronary artery disease. Ann Intern Med 1978;89:1–5.
226. Schang SJ, Pepine CJ. Transient asymptomatic S-T segment depres-
sion during daily activity. Am J Cardiol 1977;39:396–402.
227. Deedwania PC, Carbajal EV. Silent myocardial ischemia: a clinical
perspective. Arch Intern Med 1991;151:2373–82.
228. Deedwania PC, Carbajal EV. Prevalence and patterns of silent
myocardial ischemia during daily life in stable angina patients
receiving conventional antianginal drug therapy. Am J Cardiol
1990;65:1090–6.
229. Cohn PF. Silent myocardial ischemia: dimensions of the problem in
patients with and without angina. Am J Med 1986;80:3–8.
230. Gottlieb SO, Weisfeldt ML, Ouyang P, et al. Silent ischemia as a
marker for early unfavorable outcomes in patients with unstable
angina. N Engl J Med 1986;314:1214–9.
231. Rocco MB, Nabel EG, Campbell S, et al. Prognostic importance of
myocardial ischemia detected by ambulatory monitoring in patients
with stable coronary artery disease. Circulation 1988;78:877–84.
232. Deedwania PC, Carbajal EV. Silent ischemia during daily life is an
independent predictor of mortality in stable angina. Circulation
1990;81:748–56.
233. Tzivoni D, Gavish A, Zin D, et al. Prognostic significance of
ischemic episodes in patients with previous myocardial infarction.
Am J Cardiol 1988;62:661–4.
234. Raby KE, Goldman L, Cook EF, et al. Long-term prognosis of
myocardial ischemia detected by Holter monitoring in peripheral
vascular disease. Am J Cardiol 1990;66:1309–13.
235. de Marchena E, Asch J, Martinez J, et al. Usefulness of persistent
silent myocardial ischemia in predicting a high cardiac event rate in
men with medically controlled, stable angina pectoris. Am J Cardiol
1994;73:390–2.
236. Yeung AC, Barry J, Orav J, et al. Effects of asymptomatic ischemia on
long-term prognosis in chronic stable coronary disease. Circulation
1991;83:1598–604.
237. Deedwania PC, Carbajal EV. Usefulness of ambulatory silent myo-
cardial ischemia added to the prognostic value of exercise test
parameters in predicting risk of cardiac death in patients with stable
angina pectoris and exercise-induced myocardial ischemia. Am J
Cardiol 1991;68:1279–86.
238. Madjlessi-Simon T, Mary-Krause M, et al. Persistent transient
myocardial ischemia despite beta-adrenergic blockade predicts a
higher risk of adverse cardiac events in patients with coronary artery
disease. J Am Coll Cardiol 1996;27:1586–91.
239. Currie P, Ashby D, Saltissi S. Prognostic significance of transient
myocardial ischemia on ambulatory monitoring after acute myocar-
dial infarction. Am J Cardiol 1993;71:773–7.
240. Gottlieb SO, Gottlieb SH, Achuff SC, et al. Silent ischemia on
Holter monitoring predicts mortality in high-risk postinfarction
patients. JAMA 1988;259:1030–5.
241. Deedwania PC. Asymptomatic ischemia during predischarge Holter
monitoring predicts poor prognosis in the postinfarction period. Am J
Cardiol 1993;71:859–61.
242. Gill JB, Cairns JA, Roberts RS, et al. Prognostic importance of
myocardial ischemia detected by ambulatory monitoring early after
acute myocardial infarction. N Engl J Med 1996;334:65–70.
243. Mulcahy D, Keegan J, Sparrow J, et al. Ischemia in the ambulatory
setting: the total ischemic burden: relation to exercise testing and
investigative and therapeutic implications. J Am Coll Cardiol 1989;
14:1166–72.
244. Deedwania PC, Carbajal EV. Exercise test predictors of ambulatory
silent ischemia during daily life in stable angina pectoris. Am J
Cardiol 1990;66:1151–6.
245. Krantz DS, Helmers KF, Bairey CN, et al. Cardiovascular reactivity
and mental stress-induced myocardial ischemia in patients with
coronary artery disease. Psychosom Med 1991;53:1–12.
246. Gabbay FH, Krantz DS, Kop WJ, et al. Triggers of myocardial
ischemia during daily life in patients with coronary artery disease:
physical and mental activities, anger and smoking. J Am Coll Cardiol
1996;27:585–92.
247. Sharaf BL, Williams DO, Miele NJ, et al. A detailed angiographic
analysis of patients with ambulatory electrocardiographic ischemia:
results from the Asymptomatic Cardiac Ischemia Pilot (ACIP) study
angiographic core laboratory. J Am Coll Cardiol 1997;29:78–84.
248. Jiang W, Babyak M, Krantz DS, et al. Mental stress-induced
myocardial ischemia and cardiac events. JAMA 1996;275:1651–6.
249. Pepine CJ, Sharaf B, Andrews TC, et al. Relation between clinical,
angiographic, and ischemic findings at baseline and ischemia-related
adverse outcomes at 1 year in the Asymptomatic Cardiac Ischemia
Pilot Study. J Am Coll Cardiol 1997;29:1483–9.
250. Raby KE, Goldman L, Creager MA, et al. Correlation between
preoperative ischemia and major cardiac events after peripheral
vascular surgery. N Engl J Med 1989;321:1296–300.
251. Raby KE, Barry J, Creager MA, et al. Detection and significance of
intraoperative and postoperative myocardial ischemia in peripheral
vascular surgery. JAMA 1992;268:222–7.
252. Mangano DT, Browner WS, Hollenberg M, et al. Association of
perioperative myocardial ischemia with cardiac morbidity and mor-
tality in men undergoing noncardiac surgery: the Study of Perioper-
ative Ischemia Research Group. N Engl J Med 1990;323:1781–8.
253. Fleisher LA, Rosenbaum SH, Nelson AH, et al. The predictive value
of preoperative silent ischemia for postoperative ischemic cardiac
events in vascular and nonvascular surgery patients. Am Heart J
1991;122:980–6.
254. Kirwin JD, Ascer E, Gennaro M, et al. Silent myocardial ischemia is
not predictive of myocardial infarction in peripheral vascular surgery
patients. Ann Vasc Surg 1993;7:27–32.
255. McPhail NV, Ruddy TD, Barber GG, et al. Cardiac risk stratifica-
tion using dipyridamole myocardial perfusion imaging and ambula-
tory ECG monitoring prior to vascular surgery. Eur J Vasc Surg
1993;7:151–5.
256. Pasternack PF, Grossi EA, Baumann FG, et al. The value of silent
myocardial ischemia monitoring in the prediction of perioperative
myocardial infarction in patients undergoing peripheral vascular
surgery. J Vasc Surg 1989;10:617–25.
257. Fleisher LA, Rosenbaum SH, Nelson AH, et al. Preoperative
dipyridamole thallium imaging and ambulatory electrocardiographic
monitoring as a predictor of perioperative cardiac events and long-
term outcome. Anesthesiology 1995;83:906–17.
258. Mangano DT, Goldman L. Preoperative assessment of patients with
known or suspected coronary disease. N Engl J Med 1995;333:
1750–6.
259. Mangano DT, Browner WS, Hollenberg M, et al. Long-term cardiac
prognosis following noncardiac surgery: the Study of Perioperative
Ischemia Research Group. JAMA 1992;268:233–9.
260. Patel DJ, Mulcahy D, Norrie J, et al. Natural variability of transient
myocardial ischaemia during daily life: an obstacle when assessing
efficacy of anti-ischaemic agents? Heart 1996;76:477–82.
261. Stone PH, Gibson RS, Glasser SP, et al. Comparison of propranolol,
944 Crawford et al. JACC Vol. 34, No. 3, 1999
ACC/AHA Guidelines for Ambulatory Electrocardiography September 1999:912–48
diltiazem, and nifedipine in the treatment of ambulatory ischemia in
patients with stable angina. Circulation 1990;82:1962–72.
262. Deedwania PC, Carbajal EV, Nelson JR, et al. Anti-ischemic effects
of atenolol versus nifedipine in patients with coronary artery disease
and ambulatory silent ischemia. J Am Coll Cardiol 1991;17:963–9.
263. Davies RF, Habibi H, Klinke WP, et al. Effect of amlodipine,
atenolol and their combination on myocardial ischemia during
treadmill exercise and ambulatory monitoring: Canadian Amlodi-
pine/Atenolol in Silent Ischemia Study (CASIS) Investigators. J Am
Coll Cardiol 1995;25:619–25.
264. Pepine CJ, Cohn PF, Deedwania PC, et al. Effects of treatment on
outcome in mildly symptomatic patients with ischemia during daily
life: the Atenolol Silent Ischemia Study (ASIST). Circulation 1994;
90:762–8.
265. Knatterud GL, Bourassa MG, Pepine CJ, et al. Effects of treatment
strategies to suppress ischemia in patients with coronary artery
disease: 12-week results of the Asymptomatic Cardiac Ischemia Pilot
(ACIP) study. J Am Coll Cardiol 1994;24:11–20.
266. Chaitman BR, Stone PH, Knatterud GL, et al. Asymptomatic
Cardiac Ischemia Pilot (ACIP) study: impact of anti-ischemia
therapy on 12-week rest electrocardiogram and exercise test out-
comes: the ACIP Investigators. J Am Coll Cardiol 1995;26:585–93.
267. Bourassa MG, Pepine CJ, Forman SA, et al. Asymptomatic Cardiac
Ischemia Pilot (ACIP) study: effects of coronary angioplasty and
coronary artery bypass graft surgery on recurrent angina and ischemia:
the ACIP investigators. J Am Coll Cardiol 1995;26:606–14.
268. Rogers WJ, Bourassa MG, Andrews TC, et al. Asymptomatic
Cardiac Ischemia Pilot (ACIP) study: outcome at 1 year for patients
with asymptomatic cardiac ischemia randomized to medical therapy
or revascularization: the ACIP Investigators. J Am Coll Cardiol
1995;26:594–605.
269. Dargie HJ, Ford I, Fox KM. Total Ischaemic Burden European Trial
(TIBET): effects of ischaemia and treatment with atenolol, nifedipine
SR and their combination on outcome in patients with chronic stable
angina: the TIBET Study Group. Eur Heart J 1996;17:104–12.
270. Von Arnim T. Prognostic significance of transient ischemic episodes:
response to treatment shows improved prognosis: results of the Total
Ischemic Burden Bisoprolol Study (TIBBs) follow-up. J Am Coll
Cardiol 1996;28:20–4.
271. Stone PH, Chaitman BR, Forman S. Prognostic significance of
myocardial ischemia detected by ambulatory electrocardiography,
exercise treadmill testing, and electrocardiogram at rest to predict
cardiac events by 1 year (the Asymptomatic Cardiac Ischemia Pilot
[ACIP] study). Am J Cardiol 1997;80:1395–401.
272. Dick M II, McFadden D, Crowley D, et al. Diagnosis and manage-
ment of cardiac rhythm disorders by transtelephonic electrocardiog-
raphy in infants and children. J Pediatr 1979;94:612–5.
273. Fyfe DA, Holmes DR, Neubauer SA, et al. Transtelephonic moni-
toring in pediatric patients with clinically suspected arrhythmias. Clin
Pediatr 1984;23:139–43.
274. Porter CJ, Gillette PC, McNamara DG. Twenty-four-hour ambu-
latory ECGs in the detection and management of cardiac arrhythmias
in infants and children. Pediatr Cardiol 1980;1:203–8.
275. Goldstein MA, Hesslein P, Dunnigan A. Efficacy of transtelephonic
electrocardiographic monitoring in pediatric patients. Am J Dis
Child 1990;144:178–82.
276. Karpawich PP, Cavitt DL, Sugalski JS. Ambulatory arrhythmia
screening in symptomatic children and young adults: comparative
effectiveness of Holter and telephone event recordings. Pediatr
Cardiol 1993;14:147–50.
277. Houyel L, Fournier A, Centazzo S, et al. Use of transtelephonic
electrocardiographic monitoring in children with suspected arrhyth-
mias. Can J Cardiol 1992;8:741–4.
278. Driscoll DJ, Jacobsen SJ, Porter CJ, et al. Syncope in children and
adolescents. J Am Coll Cardiol 1997;29:1039–45.
279. Zimetbaum P, Kim KY, Ho KK, et al. Utility of patient-activated
cardiac event recorders in general clinical practice. Am J Cardiol
1997;79:371–2.
280. Seliem MA, Benson DW, Strasburger JF, et al. Complex ventricular
ectopic activity in patients less than 20 years of age with or without
syncope, and the role of ventricular extrastimulus testing. Am J
Cardiol 1991;68:745–50.
281. Selbst SM, Ruddy RM, Clark BJ, et al. Pediatric chest pain: a
prospective study. Pediatrics 1988;82:319–23.
282. Kaden GG, Shenker IR, Gootman N. Chest pain in adolescents.
J Adolesc Health 1991;12:251–5.
283. Wolfe RR, Driscoll DJ, Gersony WM, et al. Arrhythmias in patients
with valvar aortic stenosis, valvar pulmonary stenosis, and ventricular
septal defect: results of 24-hour ECG monitoring. Circulation
1993;87 Suppl I:I89–I101.
284. Garson A Jr, Bink-Boelkens M, Hesslein PS, et al. Atrial flutter in
the young: a collaborative study of 380 cases. J Am Coll Cardiol
1985;6:871–8.
285. Cullen S, Celermajer DS, Franklin RC, et al. Prognostic significance
of ventricular arrhythmia after repair of tetralogy of Fallot: a 12-year
prospective study. J Am Coll Cardiol 1994;23:1151–5.
286. Chandar JS, Wolff GS, Garson A Jr, et al. Ventricular arrhythmias in
postoperative tetralogy of Fallot. Am J Cardiol 1990;65:655–61.
287. Garson A Jr. Ventricular arrhythmia after repair of congenital heart
disease: who needs treatment? Cardiol Young 1991;1:177–81.
288. Paul T, Marchal C, Garson A Jr. Ventricular couplets in the young:
prognosis related to underlying substrate. Am Heart J 1990;119:577–
82.
289. McKenna WJ, Franklin RC, Nihoyannopoulos P, et al. Arrhythmia
and prognosis in infants, children and adolescents with hypertrophic
cardiomyopathy. J Am Coll Cardiol 1988;11:147–53.
290. Garson A Jr, Dick M II, Fournier A, et al. The long QT syndrome
in children: an international study of 287 patients. Circulation
1993;87:1866–72.
291. Christiansen JL, Guccione P, Garson A Jr. Difference in QT interval
measurement on ambulatory ECG compared with standard ECG.
Pacing Clin Electrophysiol 1996;19:1296–1303.
292. Dewey RC, Capeless MA, Levy AM. Use of ambulatory electrocar-
diographic monitoring to identify high-risk patients with congenital
complete heart block. N Engl J Med 1987;316:835–9.
293. Zardini M, Yee R, Thakur RK, et al. Risk of sudden arrhythmic
death in the Wolff-Parkinson-White syndrome: current perspectives.
Pacing Clin Electrophysiol 1994;17:966–75.
294. Silka MJ, Kron J, Walance CG, et al. Assessment and follow-up of
pediatric survivors of sudden cardiac death. Circulation 1990;82:
341–9.
295. Joint Steering Committees of the Unexplained Cardiac Arrest Reg-
istry and of the Idiopathic Ventricular Fibrillation Registry of the
United States. Survivors of out-of-hospital cardiac arrest with appar-
ently normal heart: need for definition and standardized clinical
evaluation: Consensus Statement of the Joint Steering Committees of
the Unexplained Cardiac Arrest Registry of Europe and of the
Idiopathic Ventricular Fibrillation Registry of the United States.
Circulation 1997;95:265–72.
296. Yanagisawa A, Miyagawa M, Yotsukura M, et al. The prevalence and
prognostic significance of arrhythmias in Duchenne type muscular
dystrophy. Am Heart J 1992;124:1244–50.
297. Melacini P, Fanin M, Danieli GA, et al. Cardiac involvement in
Becker muscular dystrophy. J Am Coll Cardiol 1993;22:1927–34.
298. Fragola PV, Luzi M, Calo L, et al. Cardiac involvement in myotonic
dystrophy. Am J Cardiol 1994;74:1070–2.
299. Larsen RL, Jakacki RI, Vetter VL, et al. Electrocardiographic
changes and arrhythmias after cancer therapy in children and young
adults. Am J Cardiol 1992;70:73–7.
300. Pfammatter JP, Paul T, Lehmann C, et al. Efficacy and proarrhyth-
mia of oral sotalol in pediatric patients. J Am Coll Cardiol 1995;26:
1002–7.
301. Garson A Jr. Dosing the newer antiarrhythmic drugs in children:
considerations in pediatric pharmacology. Am J Cardiol 1986;57:
1405–7.
302. Krongrad E. Prognosis for patients with congenital heart disease and
postoperative intraventricular conduction defects. Circulation 1978;
57:867–70.
303. Fenelon G, d’Avila A, Malacky T, et al. Prognostic significance of
transient complete atrioventricular block during radiofrequency abla-
tion of atrioventricular node reentrant tachycardia. Am J Cardiol
1995;75:698–702.
304. Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced
cardiomyopathy: a reversible form of left ventricular dysfunction.
Am J Cardiol 1986;57:563–70.
945JACC Vol. 34, No. 3, 1999 Crawford et al.
September 1999:912–48 ACC/AHA Guidelines for Ambulatory Electrocardiography
Subject Index
A
ACC, staff, 939
ACC/AHA committee membership, 914
ACC/AHA Guidelines for Ambulatory
Electrocardiography (AECG), 913
ACC/AHA Task Force on Practice Guidelines, 913
Age factors. See also Elderly
ambulatory electrocardiography for syncope and,
921
AHA. See also ACC/AHA
staff, 939
Ambulatory electrocardiography, equipment. See
Equipment
American College of Cardiology. See ACC
American Heart Association. See AHA
American National Standard, 915
Amiodarone, effect on mortality rates, 930
after myocardial infarction, 924
Amplitude-modulation (AM) systems, 915
Analog format, signals recorded in, 917
Angina pectoris, ischemia during ambulatory
electrocardiography in, 933
Anginal syndrome, evaluation of, 933
Antiarrhythmic therapy, efficacy of, ambulatory
electrocardiographic monitoring of, 929-931
Antidepressants, 917
Anti-ischemic therapy, efficacy of, evaluation of, 933,
935, 936t
Arrhythmia. See also specific arrhythmia
ambulatory electrocardiographic monitoring of,
efficacy of, 934t
analysis of, 917
assessment of patients at risk for, 922, 929
in congestive heart failure, 924, 928
in diabetic neuropathy, 928
in hemodialysis patients, 928
in hypertrophic cardiomyopathy, 924, 928
indications for, 929
monitoring pharmacologic management, 929
after myocardial infarction, 922-924, 925t, 926t-
927t
in preoperative and postoperative patients, 928-
929
in systemic hypertension, 928
in valvular heart disease, 928
asymptomatic, 920
assessment of therapy for, 931
frequency and type of
reduction in, 916
variability of, 916, 930, 934t
in heart rate variability, 919
supraventricular
guidelines for assessing therapy for, 931
therapy of, monitoring of, 930
symptomatic, assessment of, 920
traditional use of ambulatory electrocardiography
for, 913
transient, 920
ventricular, 924. See also specific arrhythmia
in hypertrophic cardiomyopathy, 924
ICD for, assessment of, 932
“Arrhythmia-free interval,” 931
Artifacts
in analysis of heart rate variability, 919
distortion of ST-segment, 915
minimization of, 917
motion, 917
ATRAMI (Autonomic Tone and Reflexes after
Myocardial Infarction) study, 923–924
Atrial ectopy, 930
Atrioventricular (AV) block, congenital, 938
Atrioventricular (AV) conduction, abnormalities, 931
Atrioventricular (AV) delay, 932
Atrioventricular (AV) node blocking drugs, effects of,
monitoring of, 930
Atrium, pacing thresholds in, 932
Autonomic Tone and Reflexes after Myocardial Infarc-
tion study. See ATRAMI
B
Baroreflex sensitivity (BRS), after myocardial infarc-
tion, 923
Baseline wander, 917
Bipolar lead configurations, 916
Bradycardia, in pediatric patients, 937
C
Cardiac Arrhythmia Suppression Trial. See CAST
Cardiac events, undersensing or oversensing of, 932
Cardiomyopathy. See also Hypertrophy
dilated, 924
in pediatric patients, ambulatory
electrocardiographic monitoring of, 937
hypertrophic, 937
arrhythmias in patients with, ambulatory
electrocardiographic assessment of, 924, 928
in pediatric patients, ambulatory
electrocardiographic monitoring of, 937
Cardiovascular disease, evaluation of pediatric patients
with, 937-938
Cardioverter-defibrillator, implantable (ICD), 921,
931
effect on mortality rates, 924
function, assessment of, 931-932
recording capabilities associated with, 917
CAST (Cardiac Arrhythmia Suppression Trial), 930,
931
Catheter ablation, radiofrequency, 938
Cerebrovascular accident, 920
Chest pain, 930
in pediatric patients, 936, 937
Class I conditions
assessment of antiarrhythmic therapy, indications
for ambulatory electrocardiography for, 931
pacemaker and ICD function in, indications for
ambulatory electrocardiography to assess, 932
patients without symptoms of arrhythmia,
ambulatory electrocardiographic arrhythmia
detection to assess risk for future cardiac
events, 929
in pediatric patients, indications for ambulatory
electrocardiographic monitoring in, 938
symptoms related to rhythm disturbances,
indications for ambulatory electrocardiography
in, 921
usefulness of ambulatory electrocardiography in,
914
Class II conditions
usefulness of ambulatory electrocardiography in,
914
Class IIa conditions
assessment of antiarrhythmic therapy, indications
for ambulatory electrocardiography for, 931
ischemia monitoring, indications for ambulatory
electrocardiography for, 936
in pediatric patients, indications for ambulatory
electrocardiographic monitoring in, 938
usefulness of ambulatory electrocardiography in,
914
Class IIb conditions
assessment of antiarrhythmic therapy, indications
for ambulatory electrocardiography for, 931
ischemia monitoring, indications for ambulatory
electrocardiography for, 936
pacemaker and ICD function in, indications for
ambulatory electrocardiography to assess, 932
patients without symptoms of arrhythmia
ambulatory electrocardiographic arrhythmia
detection to assess risk for future cardiac
events, 929
ambulatory electrocardiographic heart rate
variability detection to assess risk for future
cardiac events, 929
in pediatric patients, indications for ambulatory
electrocardiographic monitoring in, 938
symptoms related to rhythm disturbances,
indications for ambulatory electrocardiography
in, 921, 922
usefulness of ambulatory electrocardiography in,
914
Class III conditions
ischemia monitoring, indications for ambulatory
electrocardiography for, 936
pacemaker and ICD function in, indications for
ambulatory electrocardiography to assess, 932
patients without symptoms of arrhythmia
ambulatory electrocardiographic arrhythmia
detection to assess risk for future cardiac
events, 929
ambulatory electrocardiographic heart rate
variability detection to assess risk for future
cardiac events, 929
in pediatric patients, indications for ambulatory
electrocardiographic monitoring in, 938
symptoms related to rhythm disturbances,
indications for ambulatory electrocardiography
in, 922
usefulness of ambulatory electrocardiography in,
914
Clinical outcome, of myocardial ischemia detected by
ambulatory electrocardiography, 933, 936t
Congenital heart defects. See also Pediatric patients
ambulatory electrocardiographic monitoring of, 937
Congestive heart failure. See Heart failure
Consciousness, loss of, 914, 920
Continuous recorders, recording
description of, 915-916
indications for, 920
uses of, 914
Contractions. See Ventricular contractions
Conventional format for recording, 915. See also
Continuous recorders
Coronary artery disease (CAD), 932
stable
incidence and prognostic significance of, studies
defining, 935t
myocardial ischemia detected by ambulatory
electrocardiography in, 933
D
Daily activities, routine recordings during, 917
Data transfer, electronic, 915
Decision making, use of ambulatory
electrocardiography for, 914
Depolarization, ventricular premature, 931
Diabetic neuropathy, heart rate variability in,
ambulatory electrocardiographic monitoring
for, 928
Diagnostic accuracy, 914
Dialysis patients. See Hemodialysis patients
Diaphoresis, 921
Digital format, recording of signal in, 915
Digitization, rate of, 919
Digoxin, 917
Distribution-based artifact in heart rate variability
determination, 919
Dizziness, 937
vertigo distinguished from, 920
E
Ectopic beats. See also Atrial ectopy; Ventricular
ectopy
number of, calculation of, 917
Ejection fraction, 924
Elderly. See also Age factors
Elderly, screening of, 929
Electrode preparation, method of, 916
Electrophysiologic studies, ambulatory
electrocardiography compared with, 930
Encainide, effect on mortality rates, 930
Equipment, ambulatory electrocardiography, 914-915
AECG recording capabilities associated with
pacemakers and ICDs, 917
continuous recorders, 915-916
electrode preparation and lead systems, 916
emerging technologies, 918
intermittent recorders, 916
playback systems and methods of analysis, 917-918
technical capacity of, 914
variability of arrhythmias and ischemia and optimal
duration of recording, 916
European Society of Cardiology (ESC), Task Force
of, 918, 919
Event recorders, 914. See also Intermittent recorders
activation of, 920, 916
long-term, 913
patient-activated, 915
uses of, 914-915
Exercise testing, 916
ischemic response during, 933
F
Facsimile, 917
False-positive changes, 935
Fibrillation. See Ventricular fibrillation
Flash cards, 915
Flecainide, effect on mortality rates, 930
Fourier transformation, 918
Frequency domain measures of heart rate variability,
919t
Frequency-modulated (FM) systems, 915
“Full disclosure,” 915
lack of, 915
G
Gender, ambulatory electrocardiography for syncope
and, 921
H
Hard drive
miniature, 915-916
portable, 915
“Healthy responder,” 930
Heart failure, arrhythmias in patients with, ambulatory
electrocardiographic assessment of, 924, 928t
Heart rate variability (HRV), 929
analysis of, 913
arrhythmia after myocardial infarction and,
assessment for, 923, 924t
components of, 918t
in congestive heart failure, 924, 928t
day-to-day variability, 919-920
in diabetic neuropathy, 928
general considerations, 918
in hypertrophic cardiomyopathy, 924
multiple markers for, 923
technical requirements for recording and analysis,
918-919
triangular index, 923
in valvular heart disease, 928
Heart rhythm, symptoms related to, assessment of
indications for ambulatory electrocardiography for,
921-922
selection of recording techniques, 920-921
specific symptoms, 921, 922t
symptomatic arrhythmias, 920
Hemodialysis patients, arrhythmias in, ambulatory
electrocardiographic monitoring for, 928
High-risk patients, in myocardial ischemia,
identification of, 933
Hypertension, systemic, arrhythmias in, ambulatory
electrocardiographic monitoring for, 928
Hypertrophy. See also Cardiomyopathy
left ventricular, in systemic hypertension, 928
I
ICD. See Cardioverter-defibrillator, implantable
In-hospital monitoring, continuous, in pediatric
patients with cardiovascular disease, 938
Intermittent recorders
description of, 916
event recorders, 914-915. See also Event recorders
indications for, 920, 921
loop recorders, 914. See also Loop recorders
for syncope, 921
uses of, 914
Internet, 917
Interobserver-intraobserver agreement, 917
Ischemia. See also Anti-ischemic therapy; Myocardial
ischemia
ambulatory electrocardiographic monitoring for, 916
analysis of, 917-918
asymptomatic, assessment of, 913
frequency of, variability of, 916
identification of, 917
Isoelectric reference point, 917
J
J-point, 917
L
Late potentials, arrhythmia after myocardial infarction
and, 923
Lead systems, types of, 916
Left ventricular function, 929
Loop recorders, 914, 916
activation of, 914
Loss-less compression method, 915
“Lossy” compression, 915
Lung disease, obstructive, 929
M
MADIT (Multicenter Automatic Defibrillator
Implantation Trial), 924
Malignancy, childhood, 938
Modem, 917
Monitors, ambulatory electrocardiography, self-
activation of, 913
Moricizine, effect on mortality rates, 930
Mortality rates, effect of antiarrhythmic drug therapy
on, 930
Motion-related artifacts, in heart rate variability
determination, 919
MSSD, 920
Multicenter Automatic Defibrillator Implantation
Trial. See MADIT
Muscular dystrophy, Duchenne or Becker, 938
Myocardial infarction
arrhythmia development after
assessment of risk for, 922-924, 925t, 926t-927t
sensitivity and specificity of noninvasive tests for
predicting, 923, 925t
prognosis after, in patients undergoing 24 hour
ambulatory electrocardiography, predicting of,
926t-927t
recent, myocardial ischemia in, 933
Myocardial ischemia
ambulatory electrocardiographic monitoring for,
932-933
limitations, 935
prevalence and predictive value, 933
role in therapeutic evaluation, 933, 935, 936t
false-positive changes, 935
transmural, 935
Myotonic dystrophies, 938
N
Near-syncope, in pediatric patients, 936, 937
Nehb J lead, inverse, 916
Neurologic symptoms, transient, in pediatric patients,
937
Neuropathy. See Diabetic neuropathy
“Noise”
baseline, 915
in R wave timing, 919
Normal populations, heart rate variability in, 919
North American Society of Pacing and
Electrophysiology (NASPE), 918, 919
O
On-line interpretations, accuracy of, 915
Overreading, 917
P
P-R segment, 917
Pacemaker, 921
function, assessment of, 931-932
in pediatric patients, monitoring of, 938
recording capabilities associated with, 917
Pacemaker activity, recording of, 916
Page-type displays, 917
Palpitations, 920
ambulatory electrocardiography for, 921, 922t
in pediatric patients, 936, 937t
Parasympathetic tone, 918
Pediatric patients. See also Congenital heart defects;
Surgery, pediatric
Pediatric patients, purpose of ambulatory
electrocardiographic monitoring in, 936, 938
evaluation after therapy or intervention, 938
evaluation of patient with known cardiovascular
disease, 937-938
evaluation of symptoms, 936-937
947JACC Vol. 34, No. 3, 1999 Crawford et al.
September 1999:912–48 ACC/AHA Guidelines for Ambulatory Electrocardiography
indications, 938
Pharmacologial management, monitoring of, 929
Playback systems, 917
rapid, 917
tape, 917
pNN50, 920, 923
Postoperative patients, arrhythmias in, ambulatory
electrocardiographic monitoring for, 928-929
PPV, 923
Preexcitation syndrome, 938
Preoperative evaluation, of patients with peripheral
vascular disease, ambulatory
electrocardiography for, 933, 936t
Preoperative patients, arrhythmias in, ambulatory
electrocardiographic monitoring for, 928-929
Proarrhythmia
concept of, 931
detection of, 931
Prolonged monitoring, 935
Q
Q wave, ischemia detection by, 917
QRS morphology, distortion of, 917
QRS-T complex
“lossy” compression of, 915
on-line analysis of, 915
QRS-T morphology, 914
for ischemia identification, 917
QT interval
dispersion, 918
increased, in proarrhythmia, 931
long QT syndrome, 937
R
R-R interval, 919
height of, histogram of, 918
R-R variability. See also Heart rate variability
analysis of, 918
monitoring of, in pharmacologic treatment, 929
R-wave, 917
peak identification, temporal accuracy of, 919
timing
errors in, 919
Rate responsivitity, 932
Recorders, AECG, 921
continuous. See Continuous recorders
intermittent. See Intermittent recorders
Recording
duration of, 918
optimal duration of, 916
of patient symptoms, technique for, 920-921
Repolarization, abnormalities, 935
rMSSD, 918, 923
S
SDANN (standard deviation of the averaged normal
sinus R-R intervals), 918
SDNN (standard deviation of all normal sinus R-R
intervals), 918, 920, 923
Shortness of breath, 921
Signal, recording of, 915
Signal averaging, 915, 918, 923, 929
Sinus rhythm, 917
Skin, preparation for electrode placement, 916
Skin resistance, 916
Solid-state format, limitations of, 915
Solid-state recording devices, 915
Spectral analysis
of heart rate variability, 918
high-frequency (H-F) component of, 918
low-frequency (L-F) component of, 918
Spectral component, of heart rate variability, 918t
ST-segment
artifactual distortion of, 915
changes, 916
causes of, 935
in myocardial ischemia, 933
deviation, 914
analysis of, 913
distortion of, 917
duration, variability in, 916
elevation, 935
interpretation, differences in, 917
in ischemia analysis, 917-918
Standard deviation of the all normal sinus R-R
intervals. See SDNN
Standard deviation of the averaged normal sinus R-R
intervals. See SDANN
Storage capacity, problems of, 915
Storage methods, 915
compressed, 915
Stress, mental, 933
Sudden death
in hypertrophic cardiomyopathy, 924
in pediatric patients, 937
risk for, 922
Superimposition scanning, 917
for ischemia analysis, 917
Supraventricular tachycardia, in pediatric patients, 937
Surgery
pediatric, 938
for congenital heart disease, ambulatory
electrocardiographic monitoring of, 937
vascular, preoperative evaluation for, ambulatory
electrocardiography for, 933, 936t
Symptoms, lack of, 933
Syncope, 920. See also Near-syncope
ambulatory electrocardiography for, 921
monitoring of, yield of AECG for, 921, 921T
in pediatric patients, 936, 937
T
T wave, 917
polarity and morphology, 935
T wave alternans, 915, 918
Tachycardia. See Ventricular tachycardia
Test cable, 916
Time-domain parameters, 918
for arrhythmia risk analysis after myocardial infarc-
tion, 923
of heart rate variability, 918t
V
V3 (CM3), 916
V5 (CM5), 916
Valve disease, arrhythmias in, ambulatory
electrocardiographic monitoring for, 928
Ventricle, pacing thresholds in, 932
Ventricular contractions, premature, in myocardial in-
farction patients, 922
Ventricular ectopy
antiarrhythmic drug therapy for, 930
frequency of, determination of, 932
after myocardial infarction, 922
predictive value of, 922, 923
in pediatric patients, 937
therapy for, efficacy of ambulatory
electrocardiographic monitoring, 929-930
in valvular heart disease, 928
Ventricular fibrillation, 924
Ventricular function, 923
Ventricular tachycardia, 924
drug therapy for, assessment of, 930
nonsustained, 920
Vertigo, distinguished from dizziness, 920
W
Wolff-Parkinson-White syndrome, 938
Writing groups, 913
948 Crawford et al. JACC Vol. 34, No. 3, 1999
ACC/AHA Guidelines for Ambulatory Electrocardiography September 1999:912–48
